

2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes - Task Force Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2018.

Expert	Type of Relationship with Industry
Achenbach Stephan	Nothing to be declared (2017-2018)
Agewall Stefan	<p>1- Financial Declaration</p> <p>A - DIRECT PERSONAL PAYMENT AS IT APPLIES TO YOU AND YOUR SPOUSE/PARTNER OR ANY OTHER MEMBER OF YOUR HOUSEHOLD, OR ANY ENTITY CONTROLLED DIRECTLY OR INDIRECTLY BY ANY OF ABOVE PERSONS: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Astra Zeneca : Antiplatelet treatment (2017) - Boehringer-Ingelheim : Antidiabetic treatment (2018)
Barbato Emanuele	<p>1- Financial Declaration</p> <p>A - DIRECT PERSONAL PAYMENT AS IT APPLIES TO YOU AND YOUR SPOUSE/PARTNER OR ANY OTHER MEMBER OF YOUR HOUSEHOLD, OR ANY ENTITY CONTROLLED DIRECTLY OR INDIRECTLY BY ANY OF ABOVE PERSONS: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Boston Scientific : Speaker fees (2018) - Abbott Vascular : Speaker fees (2018) <p>B - PAYMENT TO YOUR DEPARTMENT OR INSTITUTION OR ANY OTHER BODY LIKE AN ASSOCIATION OR SIMILAR FOR YOUR PERSONAL SERVICES: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Boston Scientific : Education courses on rotational atherectomy (2017) - Abbott Vascular : Educational courses on FFR (2017) <p>D - RESEARCH FUNDING UNDER YOUR DIRECT/PERSONAL RESPONSIBILITY (TO DEPARTMENT OR INSTITUTION) FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - St Jude Medical : Unrestricted grant for an investigator-driven study (2017)

2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes - Task Force Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2018.

Expert	Type of Relationship with Industry
Bax Jeroen	<p>1- Financial Declaration</p> <p>A - DIRECT PERSONAL PAYMENT AS IT APPLIES TO YOU AND YOUR SPOUSE/PARTNER OR ANY OTHER MEMBER OF YOUR HOUSEHOLD, OR ANY ENTITY CONTROLLED DIRECTLY OR INDIRECTLY BY ANY OF ABOVE PERSONS: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Boehringer-Ingelheim : Antiplatelets/anticoagulation-lecture (2018) - Abbott Vascular : MltraClip - speaker fees (2018) <p>B - PAYMENT TO YOUR DEPARTMENT OR INSTITUTION OR ANY OTHER BODY LIKE AN ASSOCIATION OR SIMILAR FOR YOUR PERSONAL SERVICES: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Boehringer-Ingelheim : Antiplatelets/anticoagulation-lecture (2018) - Boston Scientific : LAA closure-advisory board review (2018) <p>D - RESEARCH FUNDING UNDER YOUR DIRECT/PERSONAL RESPONSIBILITY (TO DEPARTMENT OR INSTITUTION) FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Boston Scientific : device therapy (2017-2018) - Medtronic : device therapy (2017-2018) - Biotronik : device therapy (2017-2018) - Edwards Lifesciences : transcatheter heart valves (2017-2018) - GE Healthcare : ultrasound systems (2018) <p>2- Other Positions of Influence</p> <p>2.4 - Any other interest (financial or otherwise) that should be declared in view of holding an ESC position.</p> <ul style="list-style-type: none"> - European Associate Editor JNC, Deputy Editor EHJ; (unpaid) steering committees: PROMPT trial(Medtronic) -- TAVR UNLOAD (Edwards) -- EARLY TAVR (Edwards) -- ADMIRE (GE) -- PARSIFAL-pilot (Bayer) -- PANTHEON (Bayer); (unpaid) co-chair TR Global Consensus Committee (2017) - European Associate Editor JNC, Deputy Editor EHJ; (unpaid) steering committees: TAVR UNLOAD (Edwards) -- AURORA (GE Healthcare) (2018)

2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes - Task Force Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2018.

Expert	Type of Relationship with Industry
Capodanno Davide	<p>1- Financial Declaration</p> <p>A - DIRECT PERSONAL PAYMENT AS IT APPLIES TO YOU AND YOUR SPOUSE/PARTNER OR ANY OTHER MEMBER OF YOUR HOUSEHOLD, OR ANY ENTITY CONTROLLED DIRECTLY OR INDIRECTLY BY ANY OF ABOVE PERSONS: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Bayer : Anticoagulant drugs (2017) - Daiichi Sankyo : Anticoagulant drugs (2017) - Astra Zeneca : Antiplatelet drugs (2017) - Abbott : Intravascular imaging (2017) - Cordis : PCI (2017) - Astra Zeneca : Antithrombotic therapy (2018) - Bayer : Antithrombotic therapy (2018) - Boehringer-Ingelheim : Antithrombotic therapy (2018) - Daiichi Sankyo : Antithrombotic therapy (2018) - Pfizer : Antithrombotic therapy (2018) - Abbott Vascular : Stents (2018) - Balmed : Stents (2018)
Cuisset Thomas	<p>1- Financial Declaration</p> <p>A - DIRECT PERSONAL PAYMENT AS IT APPLIES TO YOU AND YOUR SPOUSE/PARTNER OR ANY OTHER MEMBER OF YOUR HOUSEHOLD, OR ANY ENTITY CONTROLLED DIRECTLY OR INDIRECTLY BY ANY OF ABOVE PERSONS: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Medtronic : Device (2017-2018) - Sanofi Aventis : Drug company (2017-2018) - Europa Organisation : Éducation (2017-2018)

2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes - Task Force Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2018.

Expert	Type of Relationship with Industry
Deaton Christi	<p>Nothing to be declared (2018)</p> <p>1- Financial Declaration</p> <p>E - RESEARCH FUNDING (PERSONAL). - GlaxoSmithKline : COPD (patient media) (2017)</p>
Dickstein Kenneth	<p>Nothing to be declared (2018)</p> <p>1- Financial Declaration</p> <p>E - RESEARCH FUNDING (PERSONAL). - Boston Scientific : ESC CRT Survey II (2017) - Medtronic : ESC CRT Survey II (2017) - Sorin Group : ESC CRT Survey II (2017) - St Jude Medical : ESC CRT Survey II (2017) - Biotronik : ESC CRT Survey II (2017)</p>
Edvardsen Thor	<p>Nothing to be declared (2017-2018)</p>
Escaned Javier	<p>1- Financial Declaration</p> <p>A - DIRECT PERSONAL PAYMENT AS IT APPLIES TO YOU AND YOUR SPOUSE/PARTNER OR ANY OTHER MEMBER OF YOUR HOUSEHOLD, OR ANY ENTITY CONTROLLED DIRECTLY OR INDIRECTLY BY ANY OF ABOVE PERSONS: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY. - Philips Volcano : Coronary physiology, intravascular ultrasound (2017-2018) - Medtronic : Coronary stents (2017-2018) - Orbus Neich : Coronary stents (2017-2018)</p>

2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes - Task Force Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2018.

Expert	Type of Relationship with Industry
Escaned Javier	<ul style="list-style-type: none"> - Boston Scientific : Intravascular ultrasound, coronary stents (2017-2018) - Biosensors : Stents (2017-2018) - Opsens : Coronary Physiology (2018) - Abbott : Coronary physiology, optical coherence tomography, coronary stents (2018)
Funck-Brentano Christian	<p>1- Financial Declaration</p> <p>A - DIRECT PERSONAL PAYMENT AS IT APPLIES TO YOU AND YOUR SPOUSE/PARTNER OR ANY OTHER MEMBER OF YOUR HOUSEHOLD, OR ANY ENTITY CONTROLLED DIRECTLY OR INDIRECTLY BY ANY OF ABOVE PERSONS: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Janssen Belgium : Cardiac safety of non-cardiovascular drugs under development or on the market. Design of phase I/II trials. (2017) - Actelion : Comments on the cardiac pharmacodynamic results of a phase I study of a new chemical entity (2017) - Guerbet : Cardiac safety of a contrast agent (2017-2018) - Inventiva : Cardiac safety of a new chemical entity developed for systemic sclerosis (2017-2018) - Intracellular Therapies USA : Cardiac safety of an experimental non-cardiovascular drug (2017-2018) - Pierre-Fabre : Cardiac Safety of non-cardiovascular products (2017-2018) - MMV (CH) : Cardiac Safety of two antimalarial drugs (2017-2018) - Banook (CRO) : Data and Safety Monitoring Board for an antibody developed in rheumatology (2017-2018) <p>2- Other Positions of Influence</p> <p>2.3 - Membership or affiliation in political or advocacy groups working in the field of cardiology.</p> <ul style="list-style-type: none"> - Member of the Committee for Practice Guidelines - ESC (2006-2012) Member of the Task Force on the Guidelines on Stable Coronary Artery Diseases (to be issued in 2019) (2017-2018)

2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes - Task Force Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2018.

Expert	Type of Relationship with Industry
Gersh Bernard	<p>1- Financial Declaration</p> <p>A - DIRECT PERSONAL PAYMENT AS IT APPLIES TO YOU AND YOUR SPOUSE/PARTNER OR ANY OTHER MEMBER OF YOUR HOUSEHOLD, OR ANY ENTITY CONTROLLED DIRECTLY OR INDIRECTLY BY ANY OF ABOVE PERSONS: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Medtronic : Data Safety Monitoring Board (2017) - Boston Scientific : Data Safety Monitoring Board (2017) - Duke University : Data Safety Monitoring Board (2017) - Cardiovascular Research Foundation : Data Safety Monitoring Board (2017) - Teva Pharmaceutical Industries : Data Safety Monitoring Board (2017) - Duke Clinical Research Institute : Data Safety Monitoring Board (2017) - Thrombosis Research Institute : Data Safety Monitoring Board (2017) - Janssen Research & Development, LLC : Data Safety Monitoring Board (2017) - Mount Sinai St. Lukes : Data Safety Monitoring Board (2017) - Kowa Research Institute, Inc. : Data Safety Monitoring Board (2017) - Xenon Pharmaceuticals : General Consulting (2017) - Sirtex Medical Limited : General Consulting (2017) - Janssen Scientific Affairs : General Consulting (2017) - Medtronic : Consulting (2018) - Boston Scientific : Data Safety Monitoring Board-REPRISE Study (2018) <p>2- Other Positions of Influence</p> <p>2.2 - Employment in healthcare industry (including part time) during the year for which you are declaring.</p> <ul style="list-style-type: none"> - Emeritus Consultant, Mayo Clinic Rochester MN (2017)

2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes - Task Force Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2018.

Expert	Type of Relationship with Industry
Gilard Martine	<p>1- Financial Declaration</p> <p>A - DIRECT PERSONAL PAYMENT AS IT APPLIES TO YOU AND YOUR SPOUSE/PARTNER OR ANY OTHER MEMBER OF YOUR HOUSEHOLD, OR ANY ENTITY CONTROLLED DIRECTLY OR INDIRECTLY BY ANY OF ABOVE PERSONS: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Bayer Healthcare : medication (2017) - Medtronic : TAVI (2017) - Boston Scientific : Stent and Valve (2018) - Edwards Lifesciences : Stent and valve (2018) - Medtronic : Stent and Valve (2018) - Abbott Vascular : Stent and Valve (2018) <p>B - PAYMENT TO YOUR DEPARTMENT OR INSTITUTION OR ANY OTHER BODY LIKE AN ASSOCIATION OR SIMILAR FOR YOUR PERSONAL SERVICES: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Astra Zeneca : medication (2017) - Terumo Inc : OCT/stent (2017) - Abbott Vascular : Stent (2017) - Edwards Lifesciences : TAVI (2017) - GE Healthcare : Technology (2017)
Hasdai David	<p>1- Financial Declaration</p> <p>A - DIRECT PERSONAL PAYMENT AS IT APPLIES TO YOU AND YOUR SPOUSE/PARTNER OR ANY OTHER MEMBER OF YOUR HOUSEHOLD, OR ANY ENTITY CONTROLLED DIRECTLY OR INDIRECTLY BY ANY OF ABOVE PERSONS: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Astra Zeneca : brilinta (2017-2018) - Pfizer : eliquis (2017-2018)

2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes - Task Force Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2018.

Expert	Type of Relationship with Industry
Hasdai David	<ul style="list-style-type: none"> - Boehringer-Ingelheim : pradaxa (2017-2018) - Sanofi Aventis : praluent (2017-2018) - Medicines Company : rephata (2017-2018) - Bayer : xarelto (2017-2018)
Hatala Robert	<p>1- Financial Declaration</p> <p>A - DIRECT PERSONAL PAYMENT AS IT APPLIES TO YOU AND YOUR SPOUSE/PARTNER OR ANY OTHER MEMBER OF YOUR HOUSEHOLD, OR ANY ENTITY CONTROLLED DIRECTLY OR INDIRECTLY BY ANY OF ABOVE PERSONS: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Boehringer-Ingelheim : antithrombotic therapy (2017) - IRIS : clinical trials (2017) - Pfizer : antithrombotic therapy (2017-2018) - Bayer AG : antithrombotic therapy (2017-2018) - Servier : antihyoertensive therapy (2018) - Merck Sharp & Dohme : antithrombotic therapy (2018) - Boehringer-Ingelheim : antithrombotic therapy, diabetes (2018) - IRIS : clinical trials management (2018) <p>B - PAYMENT TO YOUR DEPARTMENT OR INSTITUTION OR ANY OTHER BODY LIKE AN ASSOCIATION OR SIMILAR FOR YOUR PERSONAL SERVICES: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - St Jude Medical : CRM (2017) - Medtronic : CRM (2017-2018) - Biotronik : CRM (2017-2018) - Abbott : CRM (2018)

2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes - Task Force Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2018.

Expert	Type of Relationship with Industry
Hatala Robert	<ul style="list-style-type: none"> - Sorin Group : CRM (2018) D - RESEARCH FUNDING UNDER YOUR DIRECT/PERSONAL RESPONSIBILITY (TO DEPARTMENT OR INSTITUTION) FROM HEALTHCARE INDUSTRY. - Medtronic : CRM (2017-2018)
Knuuti Juhani	<p>1- Financial Declaration</p> <p>A - DIRECT PERSONAL PAYMENT AS IT APPLIES TO YOU AND YOUR SPOUSE/PARTNER OR ANY OTHER MEMBER OF YOUR HOUSEHOLD, OR ANY ENTITY CONTROLLED DIRECTLY OR INDIRECTLY BY ANY OF ABOVE PERSONS: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - GE Healthcare : Consultancy for myocardial perfusion imaging agent (2017) - Astra Zeneca : Consultancy for a research project for ischemic heart disease (2017-2018)
Mahfoud Felix	<p>1- Financial Declaration</p> <p>A - DIRECT PERSONAL PAYMENT AS IT APPLIES TO YOU AND YOUR SPOUSE/PARTNER OR ANY OTHER MEMBER OF YOUR HOUSEHOLD, OR ANY ENTITY CONTROLLED DIRECTLY OR INDIRECTLY BY ANY OF ABOVE PERSONS: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Medtronic : Interventional Cardiology (2017-2018) - Recor : Interventional Cardiology (2017-2018) - Boehringer-Ingelheim : Cardiology (2018) - Berlin Chemie AG : Cardiology (2018) <p>D - RESEARCH FUNDING UNDER YOUR DIRECT/PERSONAL RESPONSIBILITY (TO DEPARTMENT OR INSTITUTION) FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Medtronic : Interventional Cardiology (2017-2018) - Recor : Interventional Cardiology (2017-2018)

2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes - Task Force Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2018.

Expert	Type of Relationship with Industry
Masip Josep	<p>1- Financial Declaration</p> <p>A - DIRECT PERSONAL PAYMENT AS IT APPLIES TO YOU AND YOUR SPOUSE/PARTNER OR ANY OTHER MEMBER OF YOUR HOUSEHOLD, OR ANY ENTITY CONTROLLED DIRECTLY OR INDIRECTLY BY ANY OF ABOVE PERSONS: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Novartis : Travel Grant and Speaker fees (2017) - Menarini : Travel Grant (2017-2018) <p>B - PAYMENT TO YOUR DEPARTMENT OR INSTITUTION OR ANY OTHER BODY LIKE AN ASSOCIATION OR SIMILAR FOR YOUR PERSONAL SERVICES: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Novartis : Advisor, Acute heart failure (2017) - Orion : Consultant, Heart Failure (2017) - BRAHMS GmbH : Consultant, Biomarkers (2017-2018) - Mylan : Speaker fee, dislipidemia (2018)
Muneretto Claudio	<p>1- Financial Declaration</p> <p>A - DIRECT PERSONAL PAYMENT AS IT APPLIES TO YOU AND YOUR SPOUSE/PARTNER OR ANY OTHER MEMBER OF YOUR HOUSEHOLD, OR ANY ENTITY CONTROLLED DIRECTLY OR INDIRECTLY BY ANY OF ABOVE PERSONS: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Atricure : Cardiac tissue ablation (2017-2018) <p>D - RESEARCH FUNDING UNDER YOUR DIRECT/PERSONAL RESPONSIBILITY (TO DEPARTMENT OR INSTITUTION) FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Livanova : Extracorporeal circulation (2017) - Livanova : Suturless Aortic valve (2018)
Prescott Eva	<p>1- Financial Declaration</p> <p>B - PAYMENT TO YOUR DEPARTMENT OR INSTITUTION OR ANY OTHER BODY LIKE AN ASSOCIATION OR SIMILAR FOR YOUR PERSONAL SERVICES: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Sanofi Aventis : Microvascular disease (2017)

2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes - Task Force Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2018.

Expert	Type of Relationship with Industry
Prescott Eva	- Astra Zeneca : Microvascular disease (2017-2018)
Saraste Antti	<p>1- Financial Declaration</p> <p>A - DIRECT PERSONAL PAYMENT AS IT APPLIES TO YOU AND YOUR SPOUSE/PARTNER OR ANY OTHER MEMBER OF YOUR HOUSEHOLD, OR ANY ENTITY CONTROLLED DIRECTLY OR INDIRECTLY BY ANY OF ABOVE PERSONS: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Astra Zeneca : Heart failure (2017) - Bayer : Heart failure (2017) - Actelion : Heart failure (2017) - Abbott : Structural heart disease (2017-2018) - Bayer : Coronary artery disease (2018) - Novartis : Heart failure (2018) <p>D - RESEARCH FUNDING UNDER YOUR DIRECT/PERSONAL RESPONSIBILITY (TO DEPARTMENT OR INSTITUTION) FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Astra Zeneca : Heart failure (2017) - Astra Zeneca : Heart failure, Coronary artery disease (2018)
Storey Robert	<p>1- Financial Declaration</p> <p>A - DIRECT PERSONAL PAYMENT AS IT APPLIES TO YOU AND YOUR SPOUSE/PARTNER OR ANY OTHER MEMBER OF YOUR HOUSEHOLD, OR ANY ENTITY CONTROLLED DIRECTLY OR INDIRECTLY BY ANY OF ABOVE PERSONS: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Avacta : Antithrombotic therapy (2017) - PlaqueTec : LBS Device (2017) - Actelion : P2Y12 inhibitor (2017) - Idorsia : P2Y12 inhibitor (2017) - Pfizer : Apixaban (2017-2018)

2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes - Task Force Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2018.

Expert	Type of Relationship with Industry
Storey Robert	<ul style="list-style-type: none"> - Bristol Myers Squibb : Apixaban (2017-2018) - Novartis : Canakinumab (2017-2018) - Bayer : Rivaroxaban (2017-2018) - Astra Zeneca : Ticagrelor (2017-2018) - Haemonetics : Haemostasis (2018) - PlaqueTec : Liquid biopsy system (2018) - Idorsia : Selatogrel (2018) - Thromboserin : TH-001 (2018) <p>D - RESEARCH FUNDING UNDER YOUR DIRECT/PERSONAL RESPONSIBILITY (TO DEPARTMENT OR INSTITUTION) FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - PlaqueTec : LBS device (2017) - Astra Zeneca : Ticagrelor (2017) - Astra Zeneca : Ticagrelor, acute coronary syndromes (2018) <p>2- Other Positions of Influence</p> <p>2.4 - Any other interest (financial or otherwise) that should be declared in view of holding an ESC position.</p> <ul style="list-style-type: none"> - Patent pending on aspirin (2018)
Svitil Pavel	<p>Nothing to be declared (2017-2018)</p>
Valgimigli Marco	<p>1- Financial Declaration</p> <p>A - DIRECT PERSONAL PAYMENT AS IT APPLIES TO YOU AND YOUR SPOUSE/PARTNER OR ANY OTHER MEMBER OF YOUR HOUSEHOLD, OR ANY ENTITY CONTROLLED DIRECTLY OR INDIRECTLY BY ANY OF ABOVE PERSONS: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Sinomed : Coronary stent (2017) - Astra Zeneca : Antiplatelet agents (2017-2018)

2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes - Task Force Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2018.

Expert	Type of Relationship with Industry
Valgimigli Marco	<ul style="list-style-type: none"> - Terumo Inc : Coronary stent (2017-2018) - Abbott Vascular : Coronary Stent (2017-2018) - Bayer : Oral anticoagulation (2017-2018) - Amgen : Advisory Board (2018) - Daiichi Sankyo : Consultancy -TAVI studies (2018) - Opsens : coronary stent (2018) - Alvimedica : FFR technology (2018) - Coreflow : Intracoronary catheter for the assessment and treatment of microvascular obstruction in patients with acute myocardial infarction. (2018) - Idorsia : Parenteral P2Y12 inhibitor (2018) <p>B - PAYMENT TO YOUR DEPARTMENT OR INSTITUTION OR ANY OTHER BODY LIKE AN ASSOCIATION OR SIMILAR FOR YOUR PERSONAL SERVICES: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Daiichi Sankyo : Consultancy -TAVI studies (2017) - Biosensors : Speaker Fees (2017) - Astra Zeneca : Ticagrelor (2017) <p>D - RESEARCH FUNDING UNDER YOUR DIRECT/PERSONAL RESPONSIBILITY (TO DEPARTMENT OR INSTITUTION) FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - The Medicines Company : parenteral anticoagulation (2017) - Astra Zeneca : Anti platelet agents (2017-2018) - Medicure : Antiplatelet agents (2017-2018) - Terumo Inc : Coronary stent (2017-2018)

2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes - Task Force Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2018.

Expert	Type of Relationship with Industry
Wijns William	<p>1- Financial Declaration</p> <p>A - DIRECT PERSONAL PAYMENT AS IT APPLIES TO YOU AND YOUR SPOUSE/PARTNER OR ANY OTHER MEMBER OF YOUR HOUSEHOLD, OR ANY ENTITY CONTROLLED DIRECTLY OR INDIRECTLY BY ANY OF ABOVE PERSONS: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Biotronik : device (2017) - Microport : device (2017-2018) <p>D - RESEARCH FUNDING UNDER YOUR DIRECT/PERSONAL RESPONSIBILITY (TO DEPARTMENT OR INSTITUTION) FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Microport : device (2017) <p>2- Other Positions of Influence</p> <p>2.4 - Any other interest (financial or otherwise) that should be declared in view of holding an ESC position.</p> <ul style="list-style-type: none"> - Co-Director of Euro-PCR, the official annual meeting of EAPCI, since May 2010. Chairman of PCR, since May 2012. Co-Director of PCR Africa, since February 2013. Non executive Board member and co-founder of Argonauts Partners (innovation accelerator). Please note that I have changed positions in 2016: Cardiovascular Center Aalst (Jan till April), sabbatical leave (May till September), NUIG as of October 2016. (2017) - Co-Director of EuroPCR, the official annual meeting of EAPCI, since May 2010. Chairman of PCR, since May 2012. Co-Director of PCR Africa, since February 2013. Scientific cardiology advisor Rede Optimus Research. Co-founder of Argonauts Partners (innovation accelerator). (2018)

2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2018.

Expert	Type of Relationship with Industry
Aboyans Victor	<p>1- Financial Declaration</p> <p>A - DIRECT PERSONAL PAYMENT AS IT APPLIES TO YOU AND YOUR SPOUSE/PARTNER OR ANY OTHER MEMBER OF YOUR HOUSEHOLD, OR ANY ENTITY CONTROLLED DIRECTLY OR INDIRECTLY BY ANY OF ABOVE PERSONS: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Bayer : Antithrombotic therapy (2018) - BMS/Pfizer Alliance : Antithrombotic therapy (2018) - NovoNordisk : Diabetes (2018) - Novartis : Heart Failure (2018) - Amgen : Lipid lowering therapy (2018) - Sanofi Aventis : PAD (2018) <p>D - RESEARCH FUNDING UNDER YOUR DIRECT/PERSONAL RESPONSIBILITY (TO DEPARTMENT OR INSTITUTION) FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Bayer Healthcare : PAD (2018)
Addad Faouzi	Nothing to be declared (2018)
Ainla Tiia	Nothing to be declared (2018)
Alfonso Manterola Fernando	Nothing to be declared (2018)
Aronson Doron	Nothing to be declared (2018)
Babarskiene Marija Ruta	Nothing to be declared (2018)

2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2018.

Expert	Type of Relationship with Industry
Back Magnus	Nothing to be declared (2018)
Banning Adrian Paul	<p>1- Financial Declaration</p> <p>A - DIRECT PERSONAL PAYMENT AS IT APPLIES TO YOU AND YOUR SPOUSE/PARTNER OR ANY OTHER MEMBER OF YOUR HOUSEHOLD, OR ANY ENTITY CONTROLLED DIRECTLY OR INDIRECTLY BY ANY OF ABOVE PERSONS: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Philips : IVUS (2018) - Abbott : stents (2018) - Boston Scientific : stents (2018) <p>D - RESEARCH FUNDING UNDER YOUR DIRECT/PERSONAL RESPONSIBILITY (TO DEPARTMENT OR INSTITUTION) FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Boston Scientific : stents (2018)
Beissel Jean	<p>2- Other Positions of Influence</p> <p>2.3 - Membership or affiliation in political or advocacy groups working in the field of cardiology.</p> <ul style="list-style-type: none"> - Fondation Cœur Daniel Wagner Board Member Luxembourg Resuscitation Council Vice-President Den-I Marfan Association Luxembourg Vice-President Comité de pilotage du Plan National de Lutte contre les maladies cardio-neuro-vasculaires (Gouvernement) President (2018)
Benkhedda Salim	<p>1- Financial Declaration</p> <p>A - DIRECT PERSONAL PAYMENT AS IT APPLIES TO YOU AND YOUR SPOUSE/PARTNER OR ANY OTHER MEMBER OF YOUR HOUSEHOLD, OR ANY ENTITY CONTROLLED DIRECTLY OR INDIRECTLY BY ANY OF ABOVE PERSONS: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Novartis : Report HF study (2018)
Bertelli Luca	Nothing to be declared (2018)

2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2018.

Expert	Type of Relationship with Industry
Bonaros Nikolaos	<p>1- Financial Declaration</p> <p>A - DIRECT PERSONAL PAYMENT AS IT APPLIES TO YOU AND YOUR SPOUSE/PARTNER OR ANY OTHER MEMBER OF YOUR HOUSEHOLD, OR ANY ENTITY CONTROLLED DIRECTLY OR INDIRECTLY BY ANY OF ABOVE PERSONS: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Edwards Lifesciences, Medtronic, Philips : Valvular Heart Disease (2018) <p>D - RESEARCH FUNDING UNDER YOUR DIRECT/PERSONAL RESPONSIBILITY (TO DEPARTMENT OR INSTITUTION) FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Abbott Vascular : Valvular Heart Disease (2018) - Livanova : Valvular Heart Disease (2018) - Edwards Lifesciences : Valvular Heart Disease (2018)
Bueno Hector	<p>1- Financial Declaration</p> <p>A - DIRECT PERSONAL PAYMENT AS IT APPLIES TO YOU AND YOUR SPOUSE/PARTNER OR ANY OTHER MEMBER OF YOUR HOUSEHOLD, OR ANY ENTITY CONTROLLED DIRECTLY OR INDIRECTLY BY ANY OF ABOVE PERSONS: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Pfizer : Apixaban (2018) - Bristol Myers Squibb : Apixaban (2018) - Bayer : Aspirin, rivaroxaban (2018) - Novartis : Canakinumab (2018) - MEDSCAPE-the heart.org : Inespecific (2018) - Astra Zeneca : Ticagrelor (2018) <p>E - RESEARCH FUNDING (PERSONAL).</p> <ul style="list-style-type: none"> - BMS : CV013-011 - STANDUP-AHF trial (2018) - Novartis : LCZ696 (PROMISE trial / PERSPECTIVE trial) (2018) - Astra Zeneca : Ticagrelor (EPICOR Study, THEMIS trial) (2018)

2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2018.

Expert	Type of Relationship with Industry
Bueno Hector	<p>2- Other Positions of Influence</p> <p>2.3 - Membership or affiliation in political or advocacy groups working in the field of cardiology. - Vice-president elect. Spanish Society of Cardiology (Will become VP in October 2019) FAHA (2018)</p>
Bugiardini Raffaele	<p>Nothing to be declared (2018)</p>
Bunc Matjaz	<p>1- Financial Declaration</p> <p>B - PAYMENT TO YOUR DEPARTMENT OR INSTITUTION OR ANY OTHER BODY LIKE AN ASSOCIATION OR SIMILAR FOR YOUR PERSONAL SERVICES: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY. - Medtronic : TAVI (2018)</p>
Cassar Andrew J	<p>Nothing to be declared (2018)</p>
Cayla Guillaume	<p>1- Financial Declaration</p> <p>A - DIRECT PERSONAL PAYMENT AS IT APPLIES TO YOU AND YOUR SPOUSE/PARTNER OR ANY OTHER MEMBER OF YOUR HOUSEHOLD, OR ANY ENTITY CONTROLLED DIRECTLY OR INDIRECTLY BY ANY OF ABOVE PERSONS: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Abbott Vascular : Absorb BVS (2018) - Sanofi Aventis : Alirocumab (2018) - Pfizer : Apixaban (2018) - Bristol Myers Squibb : Apixaban (2018) - Amgen : Evolocumab (2018) - Medtronic : Onyx stent, Corevalve (2018) - Biotronik : Orsiro stent (2018) - Bayer Healthcare : Rivaroxaban (2018)

2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2018.

Expert	Type of Relationship with Industry
Cayla Guillaume	<ul style="list-style-type: none"> - Europa : Seminars (2018) - Astra Zeneca : Ticagrelor (2018) <p>D - RESEARCH FUNDING UNDER YOUR DIRECT/PERSONAL RESPONSIBILITY (TO DEPARTMENT OR INSTITUTION) FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Medtronic : Corevalve (2018)
Chieffo Alaide	<p>1- Financial Declaration</p> <p>A - DIRECT PERSONAL PAYMENT AS IT APPLIES TO YOU AND YOUR SPOUSE/PARTNER OR ANY OTHER MEMBER OF YOUR HOUSEHOLD, OR ANY ENTITY CONTROLLED DIRECTLY OR INDIRECTLY BY ANY OF ABOVE PERSONS: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Abbott Vascular : Advisory board for MVD (2018) - Biosensors : CEC (2018) - Cardinal health : DES (2018) - Abiomed : Impella (2018) - GaDA : Impella (2018)
Chioncel Ovidiu	<p>1- Financial Declaration</p> <p>A - DIRECT PERSONAL PAYMENT AS IT APPLIES TO YOU AND YOUR SPOUSE/PARTNER OR ANY OTHER MEMBER OF YOUR HOUSEHOLD, OR ANY ENTITY CONTROLLED DIRECTLY OR INDIRECTLY BY ANY OF ABOVE PERSONS: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Philips : Echocardiographic (2018) <p>D - RESEARCH FUNDING UNDER YOUR DIRECT/PERSONAL RESPONSIBILITY (TO DEPARTMENT OR INSTITUTION) FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Novartis : Heart Failure (2018) - Servier : Heart Failure (2018) - Vifor International : Heart Failure (2018)

2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2018.

Expert	Type of Relationship with Industry
Clapp Brian	<p>1- Financial Declaration</p> <p>A - DIRECT PERSONAL PAYMENT AS IT APPLIES TO YOU AND YOUR SPOUSE/PARTNER OR ANY OTHER MEMBER OF YOUR HOUSEHOLD, OR ANY ENTITY CONTROLLED DIRECTLY OR INDIRECTLY BY ANY OF ABOVE PERSONS: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Abbott : Structural intervention (2018) - Boston Scientific : Structural intervention (2018)
Collet Jean-Philippe	<p>1- Financial Declaration</p> <p>A - DIRECT PERSONAL PAYMENT AS IT APPLIES TO YOU AND YOUR SPOUSE/PARTNER OR ANY OTHER MEMBER OF YOUR HOUSEHOLD, OR ANY ENTITY CONTROLLED DIRECTLY OR INDIRECTLY BY ANY OF ABOVE PERSONS: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Bristol Myers Squibb : Apixaban (2018) - Astra Zeneca : TICAGRELOR (2018) <p>D - RESEARCH FUNDING UNDER YOUR DIRECT/PERSONAL RESPONSIBILITY (TO DEPARTMENT OR INSTITUTION) FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Bristol Myers Squibb : apixaban (2018) - Medtronic : COREVALVE (2018)
Cosyns Bernard	<p>1- Financial Declaration</p> <p>A - DIRECT PERSONAL PAYMENT AS IT APPLIES TO YOU AND YOUR SPOUSE/PARTNER OR ANY OTHER MEMBER OF YOUR HOUSEHOLD, OR ANY ENTITY CONTROLLED DIRECTLY OR INDIRECTLY BY ANY OF ABOVE PERSONS: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Daiichi Sankyo : DOACS (2018) - Pfizer : Dyslipidemia (2018) - Abbott : Prosthetic valves (2018) - Medtronic : Prosthetic valves (2018)

2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2018.

Expert	Type of Relationship with Industry
Cosyns Bernard	<p>C - RECEIPT OF ROYALTIES FOR INTELLECTUAL PROPERTY. - Oxford University Press : Echocardiography (2018)</p> <p>D - RESEARCH FUNDING UNDER YOUR DIRECT/PERSONAL RESPONSIBILITY (TO DEPARTMENT OR INSTITUTION) FROM HEALTHCARE INDUSTRY. - HeartFlow : Coronary disease (2018)</p>
Crea Filippo	<p>1- Financial Declaration</p> <p>A - DIRECT PERSONAL PAYMENT AS IT APPLIES TO YOU AND YOUR SPOUSE/PARTNER OR ANY OTHER MEMBER OF YOUR HOUSEHOLD, OR ANY ENTITY CONTROLLED DIRECTLY OR INDIRECTLY BY ANY OF ABOVE PERSONS: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY. - Oxford University Press : EHJ Honarium (2018) - Novartis : Speaker fee (2018) - Servier : Speaker fee (2018) - Menarini : Speaker Fee (2018) - Bayer Healthcare : Speaker fee (2018)</p> <p>B - PAYMENT TO YOUR DEPARTMENT OR INSTITUTION OR ANY OTHER BODY LIKE AN ASSOCIATION OR SIMILAR FOR YOUR PERSONAL SERVICES: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY. - Amgen Inc : Phd Research Founding (Direct agreement between Catholic University and Amgen) (2018) - Biotronik : Phd Research Founding (Direct agreement between Catholic University and Biotronik) (2018)</p> <p>C - RECEIPT OF ROYALTIES FOR INTELLECTUAL PROPERTY. - Wolters Kluwer : Royalties (2018) - Edra SPA - Masson : Royalties (2018)</p>

2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2018.

Expert	Type of Relationship with Industry
Czerny Martin	<p>1- Financial Declaration</p> <p>A - DIRECT PERSONAL PAYMENT AS IT APPLIES TO YOU AND YOUR SPOUSE/PARTNER OR ANY OTHER MEMBER OF YOUR HOUSEHOLD, OR ANY ENTITY CONTROLLED DIRECTLY OR INDIRECTLY BY ANY OF ABOVE PERSONS: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Medtronic : Aortic disease (2018) - Terumo Inc : Aortic disease (2018)
de Grooth Gretha Johanna	<p>Nothing to be declared (2018)</p>
Delgado Victoria	<p>1- Financial Declaration</p> <p>A - DIRECT PERSONAL PAYMENT AS IT APPLIES TO YOU AND YOUR SPOUSE/PARTNER OR ANY OTHER MEMBER OF YOUR HOUSEHOLD, OR ANY ENTITY CONTROLLED DIRECTLY OR INDIRECTLY BY ANY OF ABOVE PERSONS: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Abbott Vascular : Mitraclip (2018) <p>D - RESEARCH FUNDING UNDER YOUR DIRECT/PERSONAL RESPONSIBILITY (TO DEPARTMENT OR INSTITUTION) FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - GE Healthcare : Echocardiography (2018) - Edwards Lifesciences : Transcatheter valve interventions (2018)
Dendale Paul	<p>1- Financial Declaration</p> <p>B - PAYMENT TO YOUR DEPARTMENT OR INSTITUTION OR ANY OTHER BODY LIKE AN ASSOCIATION OR SIMILAR FOR YOUR PERSONAL SERVICES: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Abbott : CV (2018) - Astra Zeneca : cv drugs (2018) - Daiichi Sankyo : cv medication (2018) - Servier : cv medication (2018)

2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2018.

Expert	Type of Relationship with Industry
Dendale Paul	<ul style="list-style-type: none"> - Bristol Myers Squibb : cv medication (2018) - Therabel : cv medication (2018) - GE Healthcare : echocardio (2018) - Biotronik : efo (2018) - Medtronic : pm (2018) - Boston Scientific : stents (2018)
Djordjevic-Dikic Ana	Nothing to be declared (2018)
Duplyakov Dmitry	<p>1- Financial Declaration</p> <p>A - DIRECT PERSONAL PAYMENT AS IT APPLIES TO YOU AND YOUR SPOUSE/PARTNER OR ANY OTHER MEMBER OF YOUR HOUSEHOLD, OR ANY ENTITY CONTROLLED DIRECTLY OR INDIRECTLY BY ANY OF ABOVE PERSONS: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Sanofi Aventis : Alirocumab (2018) - Pfizer : apixaban (2018) - Boehringer-Ingelheim : Dabigatran (2018) - Berlin Chemie AG : Ranolazine (2018) - Bayer Healthcare : Rivaroxaban (2018) - Astra Zeneca : Ticagrelor (2018)
Elezi Shpend	Nothing to be declared (2018)

2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2018.

Expert	Type of Relationship with Industry
Ferreira Santos Jose	<p>1- Financial Declaration</p> <p>A - DIRECT PERSONAL PAYMENT AS IT APPLIES TO YOU AND YOUR SPOUSE/PARTNER OR ANY OTHER MEMBER OF YOUR HOUSEHOLD, OR ANY ENTITY CONTROLLED DIRECTLY OR INDIRECTLY BY ANY OF ABOVE PERSONS: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Novo-Nordisk : Liraglutide (2018) - Bayer AG : rivaroxaban (2018)
Fitzsimons Donna	<p>1- Financial Declaration</p> <p>A - DIRECT PERSONAL PAYMENT AS IT APPLIES TO YOU AND YOUR SPOUSE/PARTNER OR ANY OTHER MEMBER OF YOUR HOUSEHOLD, OR ANY ENTITY CONTROLLED DIRECTLY OR INDIRECTLY BY ANY OF ABOVE PERSONS: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Medscape : Heart failure (2018)
Flachskampf Frank Arnold	<p>1- Financial Declaration</p> <p>A - DIRECT PERSONAL PAYMENT AS IT APPLIES TO YOU AND YOUR SPOUSE/PARTNER OR ANY OTHER MEMBER OF YOUR HOUSEHOLD, OR ANY ENTITY CONTROLLED DIRECTLY OR INDIRECTLY BY ANY OF ABOVE PERSONS: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - American College of Cardiology : Associate Editor (2018) <p>C - RECEIPT OF ROYALTIES FOR INTELLECTUAL PROPERTY.</p> <ul style="list-style-type: none"> - Thieme Verlag : book authorship / editorship (2018)
Gohlke Helmut	<p>2- Other Positions of Influence</p> <p>2.3 - Membership or affiliation in political or advocacy groups working in the field of cardiology.</p> <ul style="list-style-type: none"> - board member of Deutsche Herzstiftung (German Heart Foundation) engaging in education of the General Population on risk factors and cardiovascular prevention (2018)

2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2018.

Expert	Type of Relationship with Industry
Grove Erik Lerkevang	<p>1- Financial Declaration</p> <p>A - DIRECT PERSONAL PAYMENT AS IT APPLIES TO YOU AND YOUR SPOUSE/PARTNER OR ANY OTHER MEMBER OF YOUR HOUSEHOLD, OR ANY ENTITY CONTROLLED DIRECTLY OR INDIRECTLY BY ANY OF ABOVE PERSONS: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Portola Pharmaceuticals : Andexanet alfa (2018) - Bristol-Myers Squibb : apixaban (2018) - Boehringer-Ingelheim : dabigatran (2018) - Pfizer : dalteparin + apixaban (2018) - Merck Sharp & Dohme : Edoxaban (2018) - Bayer : rivaroxaban (2018) - Astrazeneca : ticagrelor / ACS (2018) <p>D - RESEARCH FUNDING UNDER YOUR DIRECT/PERSONAL RESPONSIBILITY (TO DEPARTMENT OR INSTITUTION) FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Astra Zeneca : Investigator in THEMIS + FLAVOUR + SATELLITE studies (2018)
Gudnason Thorarinn	Nothing to be declared (2018)
Haahr-Pedersen Sune	Nothing to be declared (2018)
Hansone Silvija	<p>1- Financial Declaration</p> <p>A - DIRECT PERSONAL PAYMENT AS IT APPLIES TO YOU AND YOUR SPOUSE/PARTNER OR ANY OTHER MEMBER OF YOUR HOUSEHOLD, OR ANY ENTITY CONTROLLED DIRECTLY OR INDIRECTLY BY ANY OF ABOVE PERSONS: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Novartis : Study with entresto (2018)

2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2018.

Expert	Type of Relationship with Industry
Hansone Silvija	<p>B - PAYMENT TO YOUR DEPARTMENT OR INSTITUTION OR ANY OTHER BODY LIKE AN ASSOCIATION OR SIMILAR FOR YOUR PERSONAL SERVICES: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Riga 1 st Hospital : Salary (2018) <p>D - RESEARCH FUNDING UNDER YOUR DIRECT/PERSONAL RESPONSIBILITY (TO DEPARTMENT OR INSTITUTION) FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Novartis : Study with Entresto (2018)
Hindricks Gerhard	<p>1- Financial Declaration</p> <p>B - PAYMENT TO YOUR DEPARTMENT OR INSTITUTION OR ANY OTHER BODY LIKE AN ASSOCIATION OR SIMILAR FOR YOUR PERSONAL SERVICES: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Abbott : Pacemaker, Ablation (2018) - Biosense Webster : Pacemaker, Ablation (2018) - Biotronik : Pacemaker, catheter (2018) <p>D - RESEARCH FUNDING UNDER YOUR DIRECT/PERSONAL RESPONSIBILITY (TO DEPARTMENT OR INSTITUTION) FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Biosense Webster : Electrophysiology, arrhythmias (2018) - Abbott : Electropysiology, arrhythmias (2018) <p>2- Other Positions of Influence</p> <p>2.4 - Any other interest (financial or otherwise) that should be declared in view of holding an ESC position.</p> <ul style="list-style-type: none"> - The Heart Center Leipzig / University Hospital for Cardiology, Cardiac Surgery and Pediatric Cardiology is part of the Helios Hospital Group. (2018)
lung Bernard	<p>1- Financial Declaration</p> <p>A - DIRECT PERSONAL PAYMENT AS IT APPLIES TO YOU AND YOUR SPOUSE/PARTNER OR ANY OTHER MEMBER OF YOUR HOUSEHOLD, OR ANY ENTITY CONTROLLED DIRECTLY OR INDIRECTLY BY ANY OF ABOVE PERSONS: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Boehringer Ingelheim : Anticoagulants (2018) - Edwards Lifesciences : Heart valve prostheses (2018)

2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2018.

Expert	Type of Relationship with Industry
James Stefan	<p>1- Financial Declaration</p> <p>A - DIRECT PERSONAL PAYMENT AS IT APPLIES TO YOU AND YOUR SPOUSE/PARTNER OR ANY OTHER MEMBER OF YOUR HOUSEHOLD, OR ANY ENTITY CONTROLLED DIRECTLY OR INDIRECTLY BY ANY OF ABOVE PERSONS: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Bayer : Anti coagulation (2018) - Boston Scientific : Stents (2018) <p>B - PAYMENT TO YOUR DEPARTMENT OR INSTITUTION OR ANY OTHER BODY LIKE AN ASSOCIATION OR SIMILAR FOR YOUR PERSONAL SERVICES: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - jansen : Anti coagulation (2018) - Medicines Company : Anti thrombotics (2018) - Astra Zeneca : Antiplatelet (2018) - Abbott : Stents (2018) - Boston Scientific : stents (2018) <p>D - RESEARCH FUNDING UNDER YOUR DIRECT/PERSONAL RESPONSIBILITY (TO DEPARTMENT OR INSTITUTION) FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Bayer : Anti coagulation (2018) - Astra Zeneca : Anti thrombotics (2018) - Boston Scientific : Stents (2018)
Juliebo Vibeke	<p>1- Financial Declaration</p> <p>A - DIRECT PERSONAL PAYMENT AS IT APPLIES TO YOU AND YOUR SPOUSE/PARTNER OR ANY OTHER MEMBER OF YOUR HOUSEHOLD, OR ANY ENTITY CONTROLLED DIRECTLY OR INDIRECTLY BY ANY OF ABOVE PERSONS: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Astra Zeneca : Advisory board fee, Antiplatelet therapy (2018) - Merck Sharp & Dohme : Speakers fee, Anticoagulation (2018)

2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2018.

Expert	Type of Relationship with Industry
Juliebo Vibeke	- Orion : Speakers fee, Norwegian Society of Cardiology (2018)
Juni Peter	<p>1- Financial Declaration</p> <p>D - RESEARCH FUNDING UNDER YOUR DIRECT/PERSONAL RESPONSIBILITY (TO DEPARTMENT OR INSTITUTION) FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Astra Zeneca : Anti-platelet Therapy (2018) - Biotronik : Drug-eluting stents (2018) - Biosensors International Group : Drug-eluting stents (2018) - The Medicines Company : Thrombin inhibitors (2018) <p>2- Other Positions of Influence</p> <p>2.4 - Any other interest (financial or otherwise) that should be declared in view of holding an ESC position.</p> <ul style="list-style-type: none"> - Peter Jüni serves as unpaid member of the steering group of trials funded by St. Jude Medical. (2018)
Kabil Hamza Mohamad Saad	Nothing to be declared (2018)
Kala Petr	<p>1- Financial Declaration</p> <p>A - DIRECT PERSONAL PAYMENT AS IT APPLIES TO YOU AND YOUR SPOUSE/PARTNER OR ANY OTHER MEMBER OF YOUR HOUSEHOLD, OR ANY ENTITY CONTROLLED DIRECTLY OR INDIRECTLY BY ANY OF ABOVE PERSONS: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Boston Scientific : interventional cardiology (2018) <p>D - RESEARCH FUNDING UNDER YOUR DIRECT/PERSONAL RESPONSIBILITY (TO DEPARTMENT OR INSTITUTION) FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Amgen Inc : biological therapy (2018) <p>E - RESEARCH FUNDING (PERSONAL).</p> <ul style="list-style-type: none"> - Amgen Inc : biological therapy (2018)

2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2018.

Expert	Type of Relationship with Industry
Kanakakis Ioannis-Georgios	<p>1- Financial Declaration</p> <p>A - DIRECT PERSONAL PAYMENT AS IT APPLIES TO YOU AND YOUR SPOUSE/PARTNER OR ANY OTHER MEMBER OF YOUR HOUSEHOLD, OR ANY ENTITY CONTROLLED DIRECTLY OR INDIRECTLY BY ANY OF ABOVE PERSONS: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY. - Bayer, Boehringer, Astra Zeneca, Novartis : speaker fees, honoraria, consultancy, advisory board fees (2018)</p>
Katrtsis Demosthenes	<p>1- Financial Declaration</p> <p>C - RECEIPT OF ROYALTIES FOR INTELLECTUAL PROPERTY. - Oxford University Press : Educatuion (2018)</p> <p>D - RESEARCH FUNDING UNDER YOUR DIRECT/PERSONAL RESPONSIBILITY (TO DEPARTMENT OR INSTITUTION) FROM HEALTHCARE INDUSTRY. - Medtronic : HF (2018)</p>
Katus Hugo	<p>1- Financial Declaration</p> <p>A - DIRECT PERSONAL PAYMENT AS IT APPLIES TO YOU AND YOUR SPOUSE/PARTNER OR ANY OTHER MEMBER OF YOUR HOUSEHOLD, OR ANY ENTITY CONTROLLED DIRECTLY OR INDIRECTLY BY ANY OF ABOVE PERSONS: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY. - Daiichi Sankyo : Anticoagulants (2018) - Bayer Vital : Anticoagulants (2018) - Astrazeneca : Antiplatelet (2018) - Roche Diagnosticsker : Biomar (2018)</p> <p>D - RESEARCH FUNDING UNDER YOUR DIRECT/PERSONAL RESPONSIBILITY (TO DEPARTMENT OR INSTITUTION) FROM HEALTHCARE INDUSTRY. - Roche Diagnosticsarker : Biomarker (2018) - Daiichi Sankyo : Xarelto (2018)</p> <p>2- Other Positions of Influence</p> <p>2.3 - Membership or affiliation in political or advocacy groups working in the field of cardiology. - President of the German Society of Cardiology (2018)</p>

2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2018.

Expert	Type of Relationship with Industry
Kaukonen Tomi	<p>1- Financial Declaration</p> <p>A - DIRECT PERSONAL PAYMENT AS IT APPLIES TO YOU AND YOUR SPOUSE/PARTNER OR ANY OTHER MEMBER OF YOUR HOUSEHOLD, OR ANY ENTITY CONTROLLED DIRECTLY OR INDIRECTLY BY ANY OF ABOVE PERSONS: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <p style="padding-left: 40px;">- Cardirad OY : Invasive cardiology (2018)</p>
Kusljugic Zumreta	<p>Nothing to be declared (2018)</p>
Landmesser Ulf	<p>1- Financial Declaration</p> <p>A - DIRECT PERSONAL PAYMENT AS IT APPLIES TO YOU AND YOUR SPOUSE/PARTNER OR ANY OTHER MEMBER OF YOUR HOUSEHOLD, OR ANY ENTITY CONTROLLED DIRECTLY OR INDIRECTLY BY ANY OF ABOVE PERSONS: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <p style="padding-left: 40px;">- Abbott : Advisory Board fees (2018)</p> <p style="padding-left: 40px;">- Medicines Company : Advisory Board fees (2018)</p> <p style="padding-left: 40px;">- Amgen : Speaker fees (2018)</p> <p style="padding-left: 40px;">- Sanofi Aventis : Speaker fees (2018)</p> <p>D - RESEARCH FUNDING UNDER YOUR DIRECT/PERSONAL RESPONSIBILITY (TO DEPARTMENT OR INSTITUTION) FROM HEALTHCARE INDUSTRY.</p> <p style="padding-left: 40px;">- Bayer AG : Research Grant (2018)</p>
Leclercq Christophe	<p>1- Financial Declaration</p> <p>A - DIRECT PERSONAL PAYMENT AS IT APPLIES TO YOU AND YOUR SPOUSE/PARTNER OR ANY OTHER MEMBER OF YOUR HOUSEHOLD, OR ANY ENTITY CONTROLLED DIRECTLY OR INDIRECTLY BY ANY OF ABOVE PERSONS: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <p style="padding-left: 40px;">- Abbott : devices (2018)</p> <p style="padding-left: 40px;">- Boston Scientific : devices (2018)</p> <p style="padding-left: 40px;">- Medtronic : devices (2018)</p>

2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2018.

Expert	Type of Relationship with Industry
Leclercq Christophe	<ul style="list-style-type: none"> - Biotronik : devices (2018) <p>B - PAYMENT TO YOUR DEPARTMENT OR INSTITUTION OR ANY OTHER BODY LIKE AN ASSOCIATION OR SIMILAR FOR YOUR PERSONAL SERVICES: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Biotronik : devices (2018)
Lettino Maddalena	<p>1- Financial Declaration</p> <p>A - DIRECT PERSONAL PAYMENT AS IT APPLIES TO YOU AND YOUR SPOUSE/PARTNER OR ANY OTHER MEMBER OF YOUR HOUSEHOLD, OR ANY ENTITY CONTROLLED DIRECTLY OR INDIRECTLY BY ANY OF ABOVE PERSONS: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Daiichi Sankyo : Anticoagulants (2018) - Pfizer : Anticoagulants (2018) - Bayer Healthcare : Antithrombotic agents, anticoagulants (2018) - Sanofi Aventis : Antithrombotic agents, anticoagulants, lipid lowering drugs (2018) - Astra Zeneca : Antithrombotic agents, statins (2018)
Lewis Basil S	<p>1- Financial Declaration</p> <p>A - DIRECT PERSONAL PAYMENT AS IT APPLIES TO YOU AND YOUR SPOUSE/PARTNER OR ANY OTHER MEMBER OF YOUR HOUSEHOLD, OR ANY ENTITY CONTROLLED DIRECTLY OR INDIRECTLY BY ANY OF ABOVE PERSONS: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Pfizer : Antithrombotics (2018) - Astra Zeneca : Diabetes (2018) - Merck Sharp & Dohme : Heart failure (2018) - CSL Behring : Lipidology, Secondary prevention (2018)

2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2018.

Expert	Type of Relationship with Industry
Lewis Basil S	<p>B - PAYMENT TO YOUR DEPARTMENT OR INSTITUTION OR ANY OTHER BODY LIKE AN ASSOCIATION OR SIMILAR FOR YOUR PERSONAL SERVICES: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Astrazeneca : Antithrombotics (2018) - Astra Zeneca : Diabetes (2018) - Pfizer : Diabetes (2018) - Merck Sharp & Dohme : Heart failure (2018) - Kowa : Lipidology (2018) - Resverlogix : Lipidology. secondary prevention (2018)
Lipiec Piotr	<p>1- Financial Declaration</p> <p>A - DIRECT PERSONAL PAYMENT AS IT APPLIES TO YOU AND YOUR SPOUSE/PARTNER OR ANY OTHER MEMBER OF YOUR HOUSEHOLD, OR ANY ENTITY CONTROLLED DIRECTLY OR INDIRECTLY BY ANY OF ABOVE PERSONS: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Bayer : cardiology (2018) - Boehringer-Ingelheim : cardiology (2018) - Novartis : cardiology (2018) - Polpharma : cardiology (2018) - Servier : cardiology (2018) - GE Healthcare : cardiology (2018) - Berlin Chemie AG : cardiology (2018) - Recordati International : cardiology (2018)

2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2018.

Expert	Type of Relationship with Industry
Matter Christian M	<p>1- Financial Declaration</p> <p>A - DIRECT PERSONAL PAYMENT AS IT APPLIES TO YOU AND YOUR SPOUSE/PARTNER OR ANY OTHER MEMBER OF YOUR HOUSEHOLD, OR ANY ENTITY CONTROLLED DIRECTLY OR INDIRECTLY BY ANY OF ABOVE PERSONS: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY. - Sanofi Aventis : Alirocumab (2018)</p> <p>B - PAYMENT TO YOUR DEPARTMENT OR INSTITUTION OR ANY OTHER BODY LIKE AN ASSOCIATION OR SIMILAR FOR YOUR PERSONAL SERVICES: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY. - Novartis : Canakinumab (2018)</p>
Metzler Bernhard	Nothing to be declared (2018)
Mirrakhimov Erkin	Nothing to be declared (2018)
Nathoe Hendrik	Nothing to be declared (2018)
Neumann Franz Josef	<p>1- Financial Declaration</p> <p>B - PAYMENT TO YOUR DEPARTMENT OR INSTITUTION OR ANY OTHER BODY LIKE AN ASSOCIATION OR SIMILAR FOR YOUR PERSONAL SERVICES: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY. - Boehringer-Ingelheim : Anticoagulant Therapy (2018) - Daiichi Sankyo : Anticoagulant therapy (2018) - Pfizer : Anticoagulant therapy (2018) - Bayer Healthcare : Anticoagulant therapy (2018) - Bristol Myers Squibb : Anticoagulant therapy (2018) - Boston Scientific : Interventional cardiology (2018)</p>

2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2018.

Expert	Type of Relationship with Industry
Neumann Franz Josef	<ul style="list-style-type: none"> - Biotronik : Interventional Cardiology (2018) - Edwards Lifesciences : Transcatheter valves (2018) - Medtronic : Transcatheter valves (2018) <p>D - RESEARCH FUNDING UNDER YOUR DIRECT/PERSONAL RESPONSIBILITY (TO DEPARTMENT OR INSTITUTION) FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Bayer Healthcare : Anticoagulant therapy (2018) - Pfizer : Anticoagulation (2018) - GlaxoSmithKline : Anticoagulation (2018) - Novartis : Heart failure (2018) - Biotronik : Interventional Cardiology (2018) - Abbott Vascular : MitraClip, Xience Stent (2018) - Boston Scientific : Stents (2018) - Edwards Lifesciences : Transcatheter Valves (2018) - Medtronic : Transcatheter Valves (2018)
Niessner Alexander	<p>1- Financial Declaration</p> <p>A - DIRECT PERSONAL PAYMENT AS IT APPLIES TO YOU AND YOUR SPOUSE/PARTNER OR ANY OTHER MEMBER OF YOUR HOUSEHOLD, OR ANY ENTITY CONTROLLED DIRECTLY OR INDIRECTLY BY ANY OF ABOVE PERSONS: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Bayer : anticoagulation (2018) - Daiichi Sankyo : anticoagulation (2018) - Pfizer : anticoagulation (2018) - Bristol Myers Squibb : anticoagulation (2018) - Boehringer-Ingelheim : anticoagulation, antidiabetic therapy (2018)

2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2018.

Expert	Type of Relationship with Industry
Niessner Alexander	<ul style="list-style-type: none"> - Novo-Nordisk : antidiabetic therapy (2018) - Astra Zeneca : antithrombotic therapy (2018) - St Jude Medical : interventional cardiology (2018) <p>D - RESEARCH FUNDING UNDER YOUR DIRECT/PERSONAL RESPONSIBILITY (TO DEPARTMENT OR INSTITUTION) FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Daiichi Sankyo : anticoagulation (2018) - Boehringer-Ingelheim : atrial fibrillation (2018)
Pagava Zurab	<p>1- Financial Declaration</p> <p>A - DIRECT PERSONAL PAYMENT AS IT APPLIES TO YOU AND YOUR SPOUSE/PARTNER OR ANY OTHER MEMBER OF YOUR HOUSEHOLD, OR ANY ENTITY CONTROLLED DIRECTLY OR INDIRECTLY BY ANY OF ABOVE PERSONS: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Berlin Chemie AG (Georgia) : Spieker fees (2018) - Servier (Georgia) : Spieker fees (2018) - AstraZeneca (Georgia) : Spieker fees (2018)
Panayi Georgios	<p>Nothing to be declared (2018)</p>
Patrono Carlo	<p>1- Financial Declaration</p> <p>A - DIRECT PERSONAL PAYMENT AS IT APPLIES TO YOU AND YOUR SPOUSE/PARTNER OR ANY OTHER MEMBER OF YOUR HOUSEHOLD, OR ANY ENTITY CONTROLLED DIRECTLY OR INDIRECTLY BY ANY OF ABOVE PERSONS: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Bayer : Aspirin, Rivaroxaban (2018) - Amgen : Cardiovascular prevention (2018) - GlaxoSmithKline : NSAIDs (2018)

2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2018.

Expert	Type of Relationship with Industry
Patrono Carlo	<p>D - RESEARCH FUNDING UNDER YOUR DIRECT/PERSONAL RESPONSIBILITY (TO DEPARTMENT OR INSTITUTION) FROM HEALTHCARE INDUSTRY. - Bayer Healthcare : Aspirin (2018)</p> <p>2- Other Positions of Influence</p> <p>2.4 - Any other interest (financial or otherwise) that should be declared in view of holding an ESC position. - Chair of the Scientific Advisory Board of the International Aspirin Foundation (2018)</p>
Peace Aaron J	<p>1- Financial Declaration</p> <p>A - DIRECT PERSONAL PAYMENT AS IT APPLIES TO YOU AND YOUR SPOUSE/PARTNER OR ANY OTHER MEMBER OF YOUR HOUSEHOLD, OR ANY ENTITY CONTROLLED DIRECTLY OR INDIRECTLY BY ANY OF ABOVE PERSONS: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY. - Biosensors : drug eluting stents and balloons (2018)</p>
Pejkov Hristo	<p>Nothing to be declared (2018)</p>
Petersen Steffen Erhard	<p>1- Financial Declaration</p> <p>A - DIRECT PERSONAL PAYMENT AS IT APPLIES TO YOU AND YOUR SPOUSE/PARTNER OR ANY OTHER MEMBER OF YOUR HOUSEHOLD, OR ANY ENTITY CONTROLLED DIRECTLY OR INDIRECTLY BY ANY OF ABOVE PERSONS: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY. - Circle Cardiovascular Imaging, Inc : Cardiac MRI and CT analysis and reporting software (2018) - Servier : Heart failure (2018)</p> <p>2- Other Positions of Influence</p> <p>2.1 - Direct ownership of shares or direct financial interest in healthcare, media, education companies or in companies related to (suppliers), or in competition with the ESC and its mission: To reduce the burden of cardiovascular disease. - Healthcare - IMAGING - I have option for shares for Circle Cardiovascular Imaging Inc. (2018)</p>

2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2018.

Expert	Type of Relationship with Industry
Petronio Anna Sonia	<p>1- Financial Declaration</p> <p>A - DIRECT PERSONAL PAYMENT AS IT APPLIES TO YOU AND YOUR SPOUSE/PARTNER OR ANY OTHER MEMBER OF YOUR HOUSEHOLD, OR ANY ENTITY CONTROLLED DIRECTLY OR INDIRECTLY BY ANY OF ABOVE PERSONS: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Boston Scientific : Percutaneous Aortic and Mitral treatment (2018) - Medtronic : Percutaneous Aortic and mitral treatment (2018) - Abbott : Percutaneous Mitral treatment (2018) <p>B - PAYMENT TO YOUR DEPARTMENT OR INSTITUTION OR ANY OTHER BODY LIKE AN ASSOCIATION OR SIMILAR FOR YOUR PERSONAL SERVICES: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Boston Scientific : TAVI research (2018)
Piccolo Raffaele	Nothing to be declared (2018)
Piepoli Massimo Francesco	Nothing to be declared (2018)
Popescu Bogdan Alexandru	<p>1- Financial Declaration</p> <p>A - DIRECT PERSONAL PAYMENT AS IT APPLIES TO YOU AND YOUR SPOUSE/PARTNER OR ANY OTHER MEMBER OF YOUR HOUSEHOLD, OR ANY ENTITY CONTROLLED DIRECTLY OR INDIRECTLY BY ANY OF ABOVE PERSONS: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - GE Healthcare : Imaging (2018)
Raber Lorenz	<p>1- Financial Declaration</p> <p>A - DIRECT PERSONAL PAYMENT AS IT APPLIES TO YOU AND YOUR SPOUSE/PARTNER OR ANY OTHER MEMBER OF YOUR HOUSEHOLD, OR ANY ENTITY CONTROLLED DIRECTLY OR INDIRECTLY BY ANY OF ABOVE PERSONS: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Sanofi Aventis : Alirocumab (2018)

2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2018.

Expert	Type of Relationship with Industry
Raber Lorenz	<ul style="list-style-type: none"> - Amgen : Evolocumab (2018) - Abbott Vascular : OCT (2018) - Bayer : Rivaroxaban (2018) <p>B - PAYMENT TO YOUR DEPARTMENT OR INSTITUTION OR ANY OTHER BODY LIKE AN ASSOCIATION OR SIMILAR FOR YOUR PERSONAL SERVICES: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - CSL Behring : research compound (2018) - Astra Zeneca : Ticagrelor (2018) <p>D - RESEARCH FUNDING UNDER YOUR DIRECT/PERSONAL RESPONSIBILITY (TO DEPARTMENT OR INSTITUTION) FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Sanofi Aventis : Alirocumab (2018) - HeartFlow : FFR CT (2018) - Abbott Vascular : OCT, FFR (2018)
Revenco Valeriu	Nothing to be declared (2018)
Riccio Carmine	Nothing to be declared (2018)
Richter Dimitrios	<p>1- Financial Declaration</p> <p>A - DIRECT PERSONAL PAYMENT AS IT APPLIES TO YOU AND YOUR SPOUSE/PARTNER OR ANY OTHER MEMBER OF YOUR HOUSEHOLD, OR ANY ENTITY CONTROLLED DIRECTLY OR INDIRECTLY BY ANY OF ABOVE PERSONS: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Edwards Lifesciences : aortic stenosis (2018) - Menarini : CAD- hypertension (2018) - Unipharma : hypertension-thrombosis (2018)

2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2018.

Expert	Type of Relationship with Industry
Richter Dimitrios	<ul style="list-style-type: none"> - Abbott : lipids (2018) - Amgen : lipids (2018) - Servier : LIPIDS (2018) - Sanofi Aventis : Lipids (2018) - Lilly : Lipids (2018) - Unilever : lipids (2018) - Merck Sharp & Dohme : lipids (2018) - Vianex : lipids (2018) - RAFARM : LIPIDS (2018) - ELPEN : LIPIDS-THROMBOSIS (2018) - Bayer Healthcare : Thrombosis (2018) - Leo Pharma : THROMBOSIS (2018) - NovaGEM CYPRUS : THROMBOSIS (2018)
Roffi Marco	<p>1- Financial Declaration</p> <p>D - RESEARCH FUNDING UNDER YOUR DIRECT/PERSONAL RESPONSIBILITY (TO DEPARTMENT OR INSTITUTION) FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Boston Scientific : Stents (2018) - Medtronic : Stents (2018) - Biotronik : stents (2018) - Terumo Inc : stents (2018) - Abbott Vascular : stents (2018)

2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2018.

Expert	Type of Relationship with Industry
Roithinger Franz Xaver	<p>1- Financial Declaration</p> <p>A - DIRECT PERSONAL PAYMENT AS IT APPLIES TO YOU AND YOUR SPOUSE/PARTNER OR ANY OTHER MEMBER OF YOUR HOUSEHOLD, OR ANY ENTITY CONTROLLED DIRECTLY OR INDIRECTLY BY ANY OF ABOVE PERSONS: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Bayer : Anticoagulation (2018) - Boehringer-Ingelheim : Anticoagulation (2018) - Daiichi Sankyo : Anticoagulation (2018) - St. Jude Medical : Devices (2018) - Merck Ges m b H : Diabetes (2018) - Astra Zeneca : Platelet inhibition (2018) <p>B - PAYMENT TO YOUR DEPARTMENT OR INSTITUTION OR ANY OTHER BODY LIKE AN ASSOCIATION OR SIMILAR FOR YOUR PERSONAL SERVICES: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Bristol Myers Squibb : Anticoagulation (2018) - Biotronik : Device Therapy (2018) - Biosense Webster : Electrophysiology (2018) <p>D - RESEARCH FUNDING UNDER YOUR DIRECT/PERSONAL RESPONSIBILITY (TO DEPARTMENT OR INSTITUTION) FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Boston Scientific : Electrophysiology (2018) - Astra Zeneca : Platelet inhibition (2018)
Sarkis Antoine	<p>1- Financial Declaration</p> <p>A - DIRECT PERSONAL PAYMENT AS IT APPLIES TO YOU AND YOUR SPOUSE/PARTNER OR ANY OTHER MEMBER OF YOUR HOUSEHOLD, OR ANY ENTITY CONTROLLED DIRECTLY OR INDIRECTLY BY ANY OF ABOVE PERSONS: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Novartis : HEART FAILURE (2018)

2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2018.

Expert	Type of Relationship with Industry
Sarkis Antoine	<ul style="list-style-type: none"> - Astra Zeneca : HYPERTENSION (2018) - Servier : HYPERTENSION (2018) - Menarini : RANOLAZINE (2018) <p>2- Other Positions of Influence</p> <p>2.3 - Membership or affiliation in political or advocacy groups working in the field of cardiology.</p> <ul style="list-style-type: none"> - WOMAN HEART HEALTH CARE CENTER. Voluntary work (2018)
Sechtem Udo	<p>1- Financial Declaration</p> <p>B - PAYMENT TO YOUR DEPARTMENT OR INSTITUTION OR ANY OTHER BODY LIKE AN ASSOCIATION OR SIMILAR FOR YOUR PERSONAL SERVICES: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Bristol Myers Squibb : Atrial fibrillation anticoagulation (2018) - Daiichi Sankyo : Atrial fibrillation, anticoagulation (2018) - Sanofi Aventis : CAD (2018) - Bayer Healthcare : Driving with heart disease, CAD (2018) - Pfizer : Gender heart disease (2018) - Novartis : Heart failure (2018) - Boehringer-Ingelheim : Heart failure, diabetes (2018)
Shlyakhto Evgeny	<p>1- Financial Declaration</p> <p>A - DIRECT PERSONAL PAYMENT AS IT APPLIES TO YOU AND YOUR SPOUSE/PARTNER OR ANY OTHER MEMBER OF YOUR HOUSEHOLD, OR ANY ENTITY CONTROLLED DIRECTLY OR INDIRECTLY BY ANY OF ABOVE PERSONS: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Krka Pharma : Arterial Hypertension (2018) - Novartis : Arterial Hypertension, Heart Failure (2018) - Merck Sharp & Dohme : Atherosclerosis (2018)

2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2018.

Expert	Type of Relationship with Industry
Shlyakhto Evgeny	<ul style="list-style-type: none"> - Boehringer-Ingelheim : Dabigatran for Atrial Fibrillation (2018) - Pfizer : General Cardiology (2018)
Sibbing Dirk	<p>1- Financial Declaration</p> <p>A - DIRECT PERSONAL PAYMENT AS IT APPLIES TO YOU AND YOUR SPOUSE/PARTNER OR ANY OTHER MEMBER OF YOUR HOUSEHOLD, OR ANY ENTITY CONTROLLED DIRECTLY OR INDIRECTLY BY ANY OF ABOVE PERSONS: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Astra Zeneca : Antiplatelets (2018) - Sanofi Aventis : Antiplatelets (2018) - Roche Diagnostics : Biomarkers in cardiovascular medicine (2018) - Bayer Healthcare : NOAC (2018) - Daiichi Sankyo : NOACS (2018) - Pfizer : NOACS (2018)
Silber Sigmund	Nothing to be declared (2018)
Simpson Iain A	Nothing to be declared (2018)
Sirenko Yuriy	<p>1- Financial Declaration</p> <p>A - DIRECT PERSONAL PAYMENT AS IT APPLIES TO YOU AND YOUR SPOUSE/PARTNER OR ANY OTHER MEMBER OF YOUR HOUSEHOLD, OR ANY ENTITY CONTROLLED DIRECTLY OR INDIRECTLY BY ANY OF ABOVE PERSONS: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Takeda, Ferrer, Bayer, local manufacturers : Antihypertensive, pulmonary hypertension specific drugs (2018)

2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2018.

Expert	Type of Relationship with Industry
Sousa Uva Miguel	<p>1- Financial Declaration</p> <p>A - DIRECT PERSONAL PAYMENT AS IT APPLIES TO YOU AND YOUR SPOUSE/PARTNER OR ANY OTHER MEMBER OF YOUR HOUSEHOLD, OR ANY ENTITY CONTROLLED DIRECTLY OR INDIRECTLY BY ANY OF ABOVE PERSONS: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Abbott : Surgical Valves (2018)
Studencan Martin	<p>1- Financial Declaration</p> <p>A - DIRECT PERSONAL PAYMENT AS IT APPLIES TO YOU AND YOUR SPOUSE/PARTNER OR ANY OTHER MEMBER OF YOUR HOUSEHOLD, OR ANY ENTITY CONTROLLED DIRECTLY OR INDIRECTLY BY ANY OF ABOVE PERSONS: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Bayer : Advisory board fees (2018) - Servier : Advisory Board fees (2018) - Bayer : Speaker fees (2018)
Sujayeva Volha	<p>Nothing to be declared (2018)</p>
Toth Kalman	<p>1- Financial Declaration</p> <p>B - PAYMENT TO YOUR DEPARTMENT OR INSTITUTION OR ANY OTHER BODY LIKE AN ASSOCIATION OR SIMILAR FOR YOUR PERSONAL SERVICES: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Amgen : amg 423, amg 145 and consultancy activities along with Advisory Board duties (2018) - Pfizer : bococizumab and consultancy activities (2018) - Berlin Chemie AG : Consultancy activities (2018) - Roche Pharma : Consultancy activities (2018) - Egis Pharma : Consultancy activities (2018) - Sandoz Hungary : Consultancy activities (2018)

2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2018.

Expert	Type of Relationship with Industry
Toth Kalman	<ul style="list-style-type: none"> - Gedeon Richter Plc. : Consultancy activities (2018) - Sanofi Aventis : Consultancy activities along with Advisory Board duties (2018) - MSD Pharma : Consultancy activities along with Advisory Board duties (2018) - Novartis : LCZ696, serelaxin and consultancy activities (2018) - Boehringer-Ingelheim : linagliptin and consultancy activities (2018) - Bayer AG : xarelto, 59-7939 and consultancy activities along with Advisory Board duties (2018) <p>D - RESEARCH FUNDING UNDER YOUR DIRECT/PERSONAL RESPONSIBILITY (TO DEPARTMENT OR INSTITUTION) FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Pfizer : bococizumab and consultancy activities (2018) <p>2- Other Positions of Influence</p> <p>2.3 - Membership or affiliation in political or advocacy groups working in the field of cardiology.</p> <ul style="list-style-type: none"> - Since 2009 I have been a member of the Hungarian College of Cardiology (2018)
Vardas Panagiotis	<p>1- Financial Declaration</p> <p>A - DIRECT PERSONAL PAYMENT AS IT APPLIES TO YOU AND YOUR SPOUSE/PARTNER OR ANY OTHER MEMBER OF YOUR HOUSEHOLD, OR ANY ENTITY CONTROLLED DIRECTLY OR INDIRECTLY BY ANY OF ABOVE PERSONS: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - European Society of Cardiology : CONSULTING FEES (2018) - DEAN MEDICUS LTD : CONSULTING FEES (2018) - Bayer : SPEAKER FEES (2018) - Boehringer-Ingelheim : SPEAKER FEES (2018) - MENARINI INTERNATIONAL : SPEAKER FEES (2018) - Servier : SPEAKER FESS AND CONSULTING FEES (2018)

2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2018.

Expert	Type of Relationship with Industry
Velchev Vasil	<p>1- Financial Declaration</p> <p>A - DIRECT PERSONAL PAYMENT AS IT APPLIES TO YOU AND YOUR SPOUSE/PARTNER OR ANY OTHER MEMBER OF YOUR HOUSEHOLD, OR ANY ENTITY CONTROLLED DIRECTLY OR INDIRECTLY BY ANY OF ABOVE PERSONS: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Medtronic : CIED (2018) - Pfizer : Eliquis (2018) - Actelion : PH (2018) - Boston Scientific : renal denervation (2018) - Bayer : xarelto (2018)
Witkowski Adam	<p>1- Financial Declaration</p> <p>A - DIRECT PERSONAL PAYMENT AS IT APPLIES TO YOU AND YOUR SPOUSE/PARTNER OR ANY OTHER MEMBER OF YOUR HOUSEHOLD, OR ANY ENTITY CONTROLLED DIRECTLY OR INDIRECTLY BY ANY OF ABOVE PERSONS: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Abbott Vascular : bioabsorbable coronary stents (2018) - Terumo Inc : coronary stents (2018) - Boston Scientific : coronary stents, IVUS, Accurate aortic valves (TAVI) (2018) - Medtronic : Evolute aortic valves (TAVI) (2018) - Edwards Lifesciences : Sapien aortic valves (TAVI) (2018)
Wohrle Jochen	<p>Nothing to be declared (2018)</p>
Yildirim Aylin	<p>Nothing to be declared (2018)</p>

2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2018.

Expert	Type of Relationship with Industry
Zamorano Gomez Jose Luis	<p>1- Financial Declaration</p> <p>A - DIRECT PERSONAL PAYMENT AS IT APPLIES TO YOU AND YOUR SPOUSE/PARTNER OR ANY OTHER MEMBER OF YOUR HOUSEHOLD, OR ANY ENTITY CONTROLLED DIRECTLY OR INDIRECTLY BY ANY OF ABOVE PERSONS: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Daiichi Sankyo : Anticoagulation Afib (2018) - Amgen : lipids (2018)
Zellweger Michael Johannes	<p>1- Financial Declaration</p> <p>B - PAYMENT TO YOUR DEPARTMENT OR INSTITUTION OR ANY OTHER BODY LIKE AN ASSOCIATION OR SIMILAR FOR YOUR PERSONAL SERVICES: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Amgen : cholesterol lowering drug (2018) <p>2- Other Positions of Influence</p> <p>2.4 - Any other interest (financial or otherwise) that should be declared in view of holding an ESC position.</p> <ul style="list-style-type: none"> - Advisory Board Member of Exploris AG, Switzerland which is a data analyzing Company dealing with artificial intelligence also in the context of coronary artery disease (Cardioexplorer). (2018)

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2018.

Expert	Type of Relationship with Industry
Aboyans Victor	<p>1- Financial Declaration</p> <p>A - DIRECT PERSONAL PAYMENT AS IT APPLIES TO YOU AND YOUR SPOUSE/PARTNER OR ANY OTHER MEMBER OF YOUR HOUSEHOLD, OR ANY ENTITY CONTROLLED DIRECTLY OR INDIRECTLY BY ANY OF ABOVE PERSONS: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Amgen : Hyperlipidemia (2017) - Novartis : Hypertension (2017) - Boehringer-Ingelheim : Oral anticoagulation (2017) - Bayer Healthcare : Oral anticoagulation (2017) - Pfizer/BMS alliance : Oral anticoagulation (2017) - Bayer : Antithrombotic therapy (2018) - BMS/Pfizer Alliance : Antithrombotic therapy (2018) - NovoNordisk : Diabetes (2018) - Novartis : Heart Failure (2018) - Amgen : Lipid lowering therapy (2018) - Sanofi Aventis : PAD (2018) <p>D - RESEARCH FUNDING UNDER YOUR DIRECT/PERSONAL RESPONSIBILITY (TO DEPARTMENT OR INSTITUTION) FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Bayer Healthcare : PAD (2018)
Baigent Colin	<p>1- Financial Declaration</p> <p>D - RESEARCH FUNDING UNDER YOUR DIRECT/PERSONAL RESPONSIBILITY (TO DEPARTMENT OR INSTITUTION) FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Boehringer-Ingelheim : Empagliflozin (2017-2018) - Novartis : Sacubitril (2017-2018) - Pfizer : Sirolimus (2017-2018)

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2018.

Expert	Type of Relationship with Industry
Collet Jean-Philippe	<p>1- Financial Declaration</p> <p>A - DIRECT PERSONAL PAYMENT AS IT APPLIES TO YOU AND YOUR SPOUSE/PARTNER OR ANY OTHER MEMBER OF YOUR HOUSEHOLD, OR ANY ENTITY CONTROLLED DIRECTLY OR INDIRECTLY BY ANY OF ABOVE PERSONS: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Bristol Myers Squibb : Lecture fees representing 2000 euros for 2017. (2017) - Roche Diagnostics : Lecture fees representing 800 euros for 2017. (2017) - Bayer Healthcare : Speaker Fees for antiplatelet therapy. This represented 2000 euros in total for 2017. (2017) - Servier : SPEAKER FEES OF 1000 EUROS IN 2017 (2017) - Bristol Myers Squibb : Apixaban (2018) - Astra Zeneca : TICAGRELOR (2018) <p>D - RESEARCH FUNDING UNDER YOUR DIRECT/PERSONAL RESPONSIBILITY (TO DEPARTMENT OR INSTITUTION) FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Boston Scientific : ACADEMIC RESEARCH DONATION TO THE ACTION FOUNDATION (www.action-fonds.org) (2017) - Bayer AG : ACADEMIC RESEARCH FUNDINGS (ADRIFT TRIALS) to the action study group (www.action-fonds.org) (2017) - Astra Zeneca : ACADEMIC RESEARCH FUNDINGS (ALPHEUS TRIAL) to the action study group (www.action-fonds.org) (2017) - Medtronic : Research fundings for Academic studies (atlantis trial) to the action study group (www.action-coeur.org) (2017) - Bristol Myers Squibb and Pfizer : Research fundings for Academic studies (atlantis trial) to the action study group (www.action-coeur.org) (2017) - Bristol Myers Squibb : apixaban (2018) - Medtronic : COREVALVE (2018)

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2018.

Expert	Type of Relationship with Industry
Delgado Victoria	<p>1- Financial Declaration</p> <p>A - DIRECT PERSONAL PAYMENT AS IT APPLIES TO YOU AND YOUR SPOUSE/PARTNER OR ANY OTHER MEMBER OF YOUR HOUSEHOLD, OR ANY ENTITY CONTROLLED DIRECTLY OR INDIRECTLY BY ANY OF ABOVE PERSONS: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Abbott Vascular : Mitraclip (2017-2018) <p>D - RESEARCH FUNDING UNDER YOUR DIRECT/PERSONAL RESPONSIBILITY (TO DEPARTMENT OR INSTITUTION) FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Boston Scientific : pacemakers (2017) - Medtronic : pacemakers (2017) - Biotronik : pacemakers (2017) - Edwards Lifesciences : valves (2017) - GE Healthcare : Echocardiography (2018) - Edwards Lifesciences : Transcatheter valve interventions (2018)
Fitzsimons Donna	<p>Nothing to be declared (2017)</p> <p>1- Financial Declaration</p> <p>A - DIRECT PERSONAL PAYMENT AS IT APPLIES TO YOU AND YOUR SPOUSE/PARTNER OR ANY OTHER MEMBER OF YOUR HOUSEHOLD, OR ANY ENTITY CONTROLLED DIRECTLY OR INDIRECTLY BY ANY OF ABOVE PERSONS: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Medscape : Heart failure (2018)
Gale Christopher Peter	<p>1- Financial Declaration</p> <p>A - DIRECT PERSONAL PAYMENT AS IT APPLIES TO YOU AND YOUR SPOUSE/PARTNER OR ANY OTHER MEMBER OF YOUR HOUSEHOLD, OR ANY ENTITY CONTROLLED DIRECTLY OR INDIRECTLY BY ANY OF ABOVE PERSONS: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Astrazeneca : ACS, heart failure (2017)

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2018.

Expert	Type of Relationship with Industry
Gale Christopher Peter	<ul style="list-style-type: none"> - Vifor Pharma : Heart failure (2017) - Novartis : heart failure, CVD (2017) - Astra Zeneca : ACS (2018) - Novartis : coronary artery disease (2018) - Bayer : coronary artery disease, AF (2018) - Vifor International : heart failure (2018) - Menarini : ischaemic heart disease (2018) <p>D - RESEARCH FUNDING UNDER YOUR DIRECT/PERSONAL RESPONSIBILITY (TO DEPARTMENT OR INSTITUTION) FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Bristol Myers Squibb : Apixiban, AF (2018)
Grobbee Diederick E	<p>1- Financial Declaration</p> <p>B - PAYMENT TO YOUR DEPARTMENT OR INSTITUTION OR ANY OTHER BODY LIKE AN ASSOCIATION OR SIMILAR FOR YOUR PERSONAL SERVICES: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Amgen : advisory board (2018) - Esperion : Steering ctt (2018) <p>D - RESEARCH FUNDING UNDER YOUR DIRECT/PERSONAL RESPONSIBILITY (TO DEPARTMENT OR INSTITUTION) FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Esperion : clinical trial lipids (2018) <p>2- Other Positions of Influence</p> <p>2.2 - Employment in healthcare industry (including part time) during the year for which you are declaring.</p> <ul style="list-style-type: none"> - chief scientific officer Julius Clinical Research Ltd (2017) - chief scientific officer Julius Clinical Research Ltd (part-time) (2018)

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2018.

Expert	Type of Relationship with Industry
Halvorsen Sigrun	<p>1- Financial Declaration</p> <p>A - DIRECT PERSONAL PAYMENT AS IT APPLIES TO YOU AND YOUR SPOUSE/PARTNER OR ANY OTHER MEMBER OF YOUR HOUSEHOLD, OR ANY ENTITY CONTROLLED DIRECTLY OR INDIRECTLY BY ANY OF ABOVE PERSONS: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Bristol Myers Squibb : Antithrombotic treatment (2017-2018) - Astra Zeneca : Anti-thrombotic treatment (2017-2018) - Boehringer-Ingelheim : Anti-thrombotic treatment (2017-2018) - Pfizer : Anti-thrombotic treatment (2017-2018) - Bayer AS : Anti-thrombotic treatment (2017-2018) - Sanofi Aventis : Cholesterol lowering treatment (2017-2018) <p>B - PAYMENT TO YOUR DEPARTMENT OR INSTITUTION OR ANY OTHER BODY LIKE AN ASSOCIATION OR SIMILAR FOR YOUR PERSONAL SERVICES: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Novartis : Heart failure (2017-2018)
Hindricks Gerhard	<p>1- Financial Declaration</p> <p>B - PAYMENT TO YOUR DEPARTMENT OR INSTITUTION OR ANY OTHER BODY LIKE AN ASSOCIATION OR SIMILAR FOR YOUR PERSONAL SERVICES: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Abbott : Pacemaker, Ablation (2017-2018) - Biosense Webster : Pacemaker, Ablation (2017-2018) - Biotronik : Pacemaker, catheter (2017-2018) <p>D - RESEARCH FUNDING UNDER YOUR DIRECT/PERSONAL RESPONSIBILITY (TO DEPARTMENT OR INSTITUTION) FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Abbott, Biotronik, Medtronic, Boston Scientific : Electrophysiology, arrhythmias (2017) - Biosense Webster : Electrophysiology, arrhythmias (2018) - Abbott : Electrophysiology, arrhythmias (2018)

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2018.

Expert	Type of Relationship with Industry
Hindricks Gerhard	<p>2- Other Positions of Influence</p> <p>2.4 - Any other interest (financial or otherwise) that should be declared in view of holding an ESC position.</p> <ul style="list-style-type: none"> - The Heart Center Leipzig / University Hospital for Cardiology, Cardiac Surgery and Pediatric Cardiology is part of the Helios Hospital Group. (2017-2018)
lung Bernard	<p>1- Financial Declaration</p> <p>A - DIRECT PERSONAL PAYMENT AS IT APPLIES TO YOU AND YOUR SPOUSE/PARTNER OR ANY OTHER MEMBER OF YOUR HOUSEHOLD, OR ANY ENTITY CONTROLLED DIRECTLY OR INDIRECTLY BY ANY OF ABOVE PERSONS: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Novartis : Heart failure drugs (2017) - Boehringer Ingelheim : Anticoagulants (2017-2018) - Edwards Lifesciences : Heart valve prostheses (2017-2018)
Juni Peter	<p>1- Financial Declaration</p> <p>D - RESEARCH FUNDING UNDER YOUR DIRECT/PERSONAL RESPONSIBILITY (TO DEPARTMENT OR INSTITUTION) FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Astra Zeneca : Anti-platelet Therapy (2017-2018) - Biotronik : Drug-eluting stents (2017-2018) - Biosensors International Group : Drug-eluting stents (2017-2018) - The Medicines Company : Thrombin inhibitors (2017-2018) <p>2- Other Positions of Influence</p> <p>2.4 - Any other interest (financial or otherwise) that should be declared in view of holding an ESC position.</p> <ul style="list-style-type: none"> - Peter Jüni has received research grants to the institution from Astra Zeneca, Biotronik, Biosensors International, Eli Lilly and The Medicines Company, and serves as unpaid member of the steering group of trials funded by Astra Zeneca, Biotronik, Biosensors, St. Jude Medical and The Medicines Company. (2017) - Peter Jüni serves as unpaid member of the steering group of trials funded by St. Jude Medical. (2018)

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2018.

Expert	Type of Relationship with Industry
Katus Hugo	<p>1- Financial Declaration</p> <p>A - DIRECT PERSONAL PAYMENT AS IT APPLIES TO YOU AND YOUR SPOUSE/PARTNER OR ANY OTHER MEMBER OF YOUR HOUSEHOLD, OR ANY ENTITY CONTROLLED DIRECTLY OR INDIRECTLY BY ANY OF ABOVE PERSONS: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Daiichi Sankyo : Lixiana_NOAK (2017) - Astra Zeneca : Ticagrelor (2017) - Bayer Vital : Xarelto-NOAK (2017) - Daiichi Sankyo : Anticoagulants (2018) - Bayer Vital : Anticoagulants (2018) - Astrazeneca : Antiplatelet (2018) - Roche Diagnosticsker : Biomar (2018) <p>D - RESEARCH FUNDING UNDER YOUR DIRECT/PERSONAL RESPONSIBILITY (TO DEPARTMENT OR INSTITUTION) FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - St Jude Medical : Biobank (2017) - Philips : MRT (2017) - Roche Diagnosticsarker : Biomarker (2018) - Daiichi Sankyo : Xarelto (2018) <p>2- Other Positions of Influence</p> <p>2.3 - Membership or affiliation in political or advocacy groups working in the field of cardiology.</p> <ul style="list-style-type: none"> - President of the German Society of Cardiology (2018)

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2018.

Expert	Type of Relationship with Industry
Landmesser Ulf	<p>1- Financial Declaration</p> <p>A - DIRECT PERSONAL PAYMENT AS IT APPLIES TO YOU AND YOUR SPOUSE/PARTNER OR ANY OTHER MEMBER OF YOUR HOUSEHOLD, OR ANY ENTITY CONTROLLED DIRECTLY OR INDIRECTLY BY ANY OF ABOVE PERSONS: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Abbott : Advisory Board fees (2017-2018) - Medicines Company : Advisory Board fees (2017-2018) - Amgen : Speaker fees (2017-2018) - Sanofi Aventis : Speaker fees (2017-2018) <p>D - RESEARCH FUNDING UNDER YOUR DIRECT/PERSONAL RESPONSIBILITY (TO DEPARTMENT OR INSTITUTION) FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Bayer AG : Research Grant (2017-2018)
Leclercq Christophe	<p>1- Financial Declaration</p> <p>A - DIRECT PERSONAL PAYMENT AS IT APPLIES TO YOU AND YOUR SPOUSE/PARTNER OR ANY OTHER MEMBER OF YOUR HOUSEHOLD, OR ANY ENTITY CONTROLLED DIRECTLY OR INDIRECTLY BY ANY OF ABOVE PERSONS: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Livanova : devices (2017) - Abbott : devices (2017-2018) - Boston Scientific : devices (2017-2018) - Medtronic : devices (2017-2018) - Biotronik : devices (2017-2018) <p>B - PAYMENT TO YOUR DEPARTMENT OR INSTITUTION OR ANY OTHER BODY LIKE AN ASSOCIATION OR SIMILAR FOR YOUR PERSONAL SERVICES: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Biotronik : devices (2018)

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2018.

Expert	Type of Relationship with Industry
Leclercq Christophe	<p>D - RESEARCH FUNDING UNDER YOUR DIRECT/PERSONAL RESPONSIBILITY (TO DEPARTMENT OR INSTITUTION) FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Biotronik : devices (2017)
Lettino Maddalena	<p>1- Financial Declaration</p> <p>A - DIRECT PERSONAL PAYMENT AS IT APPLIES TO YOU AND YOUR SPOUSE/PARTNER OR ANY OTHER MEMBER OF YOUR HOUSEHOLD, OR ANY ENTITY CONTROLLED DIRECTLY OR INDIRECTLY BY ANY OF ABOVE PERSONS: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Daiichi Sankyo : Antithrombotic agents, anticoagulants (2017) - Bristol Myers Squibb : Antithrombotic agents, anticoagulants (2017) - Amgen : Lipid lowering drugs (2017) - Pfizer : Anticoagulants (2017-2018) - Bayer Healthcare : Antithrombotic agents, anticoagulants (2017-2018) - Sanofi Aventis : Antithrombotic agents, anticoagulants, lipid lowering drugs (2017-2018) - Astra Zeneca : Antithrombotic agents, statins (2017-2018) - Daiichi Sankyo : Anticoagulants (2018)
Lewis Basil S	<p>1- Financial Declaration</p> <p>A - DIRECT PERSONAL PAYMENT AS IT APPLIES TO YOU AND YOUR SPOUSE/PARTNER OR ANY OTHER MEMBER OF YOUR HOUSEHOLD, OR ANY ENTITY CONTROLLED DIRECTLY OR INDIRECTLY BY ANY OF ABOVE PERSONS: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Pfizer : Antithrombotics (2017-2018) - Merck Sharp & Dohme : Heart failure (2017-2018) - Astra Zeneca : Diabetes (2018) - CSL Behring : Lipidology, Secondary prevention (2018)

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2018.

Expert	Type of Relationship with Industry
Lewis Basil S	<p>B - PAYMENT TO YOUR DEPARTMENT OR INSTITUTION OR ANY OTHER BODY LIKE AN ASSOCIATION OR SIMILAR FOR YOUR PERSONAL SERVICES: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Novartis : Heart failure (2017) - Pfizer : Lipidology (2017) - Astrazeneca : Antithrombotics (2017-2018) - Astra Zeneca : Diabetes (2017-2018) - Pfizer : Diabetes (2017-2018) - Merck Sharp & Dohme : Heart failure (2017-2018) - Kowa : Lipidology (2017-2018) - Resverlogix : Lipidology. secondary prevention (2018)
Merkely Bela	<p>1- Financial Declaration</p> <p>A - DIRECT PERSONAL PAYMENT AS IT APPLIES TO YOU AND YOUR SPOUSE/PARTNER OR ANY OTHER MEMBER OF YOUR HOUSEHOLD, OR ANY ENTITY CONTROLLED DIRECTLY OR INDIRECTLY BY ANY OF ABOVE PERSONS: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Sanofi Aventis : ACS (2017) - Medtronic : CRT course (2017-2018) - Abbott : CRT/ICD (2017-2018) - Biotronik : ICD/CRT (2017-2018) - Astra Zeneca : HF (2018) <p>B - PAYMENT TO YOUR DEPARTMENT OR INSTITUTION OR ANY OTHER BODY LIKE AN ASSOCIATION OR SIMILAR FOR YOUR PERSONAL SERVICES: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Abbott : cardiac rhythm management (2017) - Medtronic : cardiac rhythm management (2017-2018)

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2018.

Expert	Type of Relationship with Industry
Merkely Bela	- Boston Scientific : CRT (2017-2018)
Mueller Christian Eugen	<p>1- Financial Declaration</p> <p>B - PAYMENT TO YOUR DEPARTMENT OR INSTITUTION OR ANY OTHER BODY LIKE AN ASSOCIATION OR SIMILAR FOR YOUR PERSONAL SERVICES: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Servier : Antihypertensive (2017) - Siemens Healthcare : Diagnostics (2017) - Singulex : Diagnostics (2017) - Boehringer-Ingelheim : Antidiabetics (2017-2018) - Roche Diagnostics : Diagnostics (2017-2018) - Sanofi Aventis : Lipid lowering (2017-2018) - Indorsia : Antiplatelet therapy (2018) - Amgen : Lipid-lowering (2018) <p>D - RESEARCH FUNDING UNDER YOUR DIRECT/PERSONAL RESPONSIBILITY (TO DEPARTMENT OR INSTITUTION) FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Beckman Coulter : Diagnostics (2017-2018) - OrthoClinical Diagnostics : Diagnostics (2017-2018) - Singulex : Diagnostics (2017-2018) - Abbott Laboratories : Diagnostics (2017-2018) - Roche Diagnostics : Diagnostics (2017-2018) - Siemens : Diagnostics (2017-2018) - Sphingotec : Diagnostics (2017-2018) - quidel : Diagnostics (2018)

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2018.

Expert	Type of Relationship with Industry
Petersen Steffen Erhard	<p>1- Financial Declaration</p> <p>A - DIRECT PERSONAL PAYMENT AS IT APPLIES TO YOU AND YOUR SPOUSE/PARTNER OR ANY OTHER MEMBER OF YOUR HOUSEHOLD, OR ANY ENTITY CONTROLLED DIRECTLY OR INDIRECTLY BY ANY OF ABOVE PERSONS: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Circle Cardiovascular Imaging, Inc : Cardiac MRI and CT analysis and reporting software (2017-2018) - Servier : Heart failure (2018) <p>2- Other Positions of Influence</p> <p>2.1 - Direct ownership of shares or direct financial interest in healthcare, media, education companies or in companies related to (suppliers), or in competition with the ESC and its mission: To reduce the burden of cardiovascular disease.</p> <ul style="list-style-type: none"> - Healthcare - IMAGING (2017) - Healthcare - IMAGING - I have option for shares for Circle Cardiovascular Imaging Inc. (2018)
Petronio Anna Sonia	<p>1- Financial Declaration</p> <p>A - DIRECT PERSONAL PAYMENT AS IT APPLIES TO YOU AND YOUR SPOUSE/PARTNER OR ANY OTHER MEMBER OF YOUR HOUSEHOLD, OR ANY ENTITY CONTROLLED DIRECTLY OR INDIRECTLY BY ANY OF ABOVE PERSONS: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Abbott : MitraClip (2017) - Boston Scientific : TAVI (2017) - Medtronic : TAVI (2017) - Boston Scientific : Percutaneous Aortic and Mitral treatment (2018) - Medtronic : Percutaneous Aortic and mitral treatment (2018) - Abbott : Percutaneous Mitral treatment (2018) <p>B - PAYMENT TO YOUR DEPARTMENT OR INSTITUTION OR ANY OTHER BODY LIKE AN ASSOCIATION OR SIMILAR FOR YOUR PERSONAL SERVICES: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Boston Scientific : TAVI research (2018)

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2018.

Expert	Type of Relationship with Industry
Priori Silvia Giuliana	<p>1- Financial Declaration</p> <p>A - DIRECT PERSONAL PAYMENT AS IT APPLIES TO YOU AND YOUR SPOUSE/PARTNER OR ANY OTHER MEMBER OF YOUR HOUSEHOLD, OR ANY ENTITY CONTROLLED DIRECTLY OR INDIRECTLY BY ANY OF ABOVE PERSONS: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY. - Boston Scientific : Cardiac device (2017-2018)</p> <p>B - PAYMENT TO YOUR DEPARTMENT OR INSTITUTION OR ANY OTHER BODY LIKE AN ASSOCIATION OR SIMILAR FOR YOUR PERSONAL SERVICES: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY. - Audentes Rx : Gene therapy (2017-2018)</p> <p>D - RESEARCH FUNDING UNDER YOUR DIRECT/PERSONAL RESPONSIBILITY (TO DEPARTMENT OR INSTITUTION) FROM HEALTHCARE INDUSTRY. - Takeda Pharmaceuticals : antiarrhythmic drugs (2017-2018)</p>
Richter Dimitrios	<p>1- Financial Declaration</p> <p>A - DIRECT PERSONAL PAYMENT AS IT APPLIES TO YOU AND YOUR SPOUSE/PARTNER OR ANY OTHER MEMBER OF YOUR HOUSEHOLD, OR ANY ENTITY CONTROLLED DIRECTLY OR INDIRECTLY BY ANY OF ABOVE PERSONS: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY. - Novo-Nordisk : diabetes (2017) - Novartis : hypertension (2017) - Galenica : Lipids (2017) - Teva Pharmaceutical Industries : lipids, hypertension (2017) - Edwards Lifesciences : aortic stenosis (2017-2018) - Menarini : CAD- hypertension (2017-2018) - Unipharma : hypertension-thrombosis (2017-2018) - Abbott : lipids (2017-2018) - Amgen : lipids (2017-2018)</p>

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2018.

Expert	Type of Relationship with Industry
Richter Dimitrios	<ul style="list-style-type: none"> - Sanofi Aventis : Lipids (2017-2018) - Lilly : Lipids (2017-2018) - Unilever : lipids (2017-2018) - Merck Sharp & Dohme : lipids (2017-2018) - Vianex : lipids (2017-2018) - Bayer Healthcare : Thrombosis (2017-2018) - Servier : LIPIDS (2018) - RAFARM : LIPIDS (2018) - ELPEN : LIPIDS-THROMBOSIS (2018) - Leo Pharma : THROMBOSIS (2018) - NovaGEM CYPRUS : THROMBOSIS (2018)
Roffi Marco	<p>1- Financial Declaration</p> <p>D - RESEARCH FUNDING UNDER YOUR DIRECT/PERSONAL RESPONSIBILITY (TO DEPARTMENT OR INSTITUTION) FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Boston Scientific : Stents (2017-2018) - Medtronic : Stents (2017-2018) - Biotronik : stents (2017-2018) - Terumo Inc : stents (2017-2018) - Abbott Vascular : stents (2017-2018)

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2018.

Expert	Type of Relationship with Industry
Shlyakhto Evgeny	<p>1- Financial Declaration</p> <p>A - DIRECT PERSONAL PAYMENT AS IT APPLIES TO YOU AND YOUR SPOUSE/PARTNER OR ANY OTHER MEMBER OF YOUR HOUSEHOLD, OR ANY ENTITY CONTROLLED DIRECTLY OR INDIRECTLY BY ANY OF ABOVE PERSONS: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Krka Pharma : Arterial Hypertension (2017-2018) - Novartis : Arterial Hypertension, Heart Failure (2017-2018) - Merck Sharp & Dohme : Atherosclerosis (2017-2018) - Boehringer-Ingelheim : Dabigatran for Atrial Fibrillation (2017-2018) - Pfizer : General Cardiology (2017-2018)
Simpson Iain A	<p>Nothing to be declared (2018)</p> <p>2- Other Positions of Influence</p> <p>2.4 - Any other interest (financial or otherwise) that should be declared in view of holding an ESC position.</p> <ul style="list-style-type: none"> - Member and Past President of the British Cardiovascular Society Member of the Management Board of the American College of Cardiology National Cardiovascular Data Registries (2017)
Sousa Uva Miguel	<p>Nothing to be declared (2017)</p> <p>1- Financial Declaration</p> <p>A - DIRECT PERSONAL PAYMENT AS IT APPLIES TO YOU AND YOUR SPOUSE/PARTNER OR ANY OTHER MEMBER OF YOUR HOUSEHOLD, OR ANY ENTITY CONTROLLED DIRECTLY OR INDIRECTLY BY ANY OF ABOVE PERSONS: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Abbott : Surgical Valves (2018)

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2018.

Expert	Type of Relationship with Industry
Touyz Rhian	<p>1- Financial Declaration</p> <p>B - PAYMENT TO YOUR DEPARTMENT OR INSTITUTION OR ANY OTHER BODY LIKE AN ASSOCIATION OR SIMILAR FOR YOUR PERSONAL SERVICES: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Novartis : antihypertensive drugs (2017-2018) - Alnylam : antihypertensive drugs (2017-2018) <p>E - RESEARCH FUNDING (PERSONAL).</p> <ul style="list-style-type: none"> - British Heart Foundation : Hypertension research (2017-2018) - Medical Research Council, UK : Hypertension research (2017-2018) <p>2- Other Positions of Influence</p> <p>2.3 - Membership or affiliation in political or advocacy groups working in the field of cardiology.</p> <ul style="list-style-type: none"> - American Heart Association International Society of Hypertension British Irish Hypertension Society (2017-2018)
Windecker Stephan	<p>1- Financial Declaration</p> <p>B - PAYMENT TO YOUR DEPARTMENT OR INSTITUTION OR ANY OTHER BODY LIKE AN ASSOCIATION OR SIMILAR FOR YOUR PERSONAL SERVICES: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Bayer AG : General Cardiology (2017) - Abbott : Invasive Cardiology (2017) - Boston Scientific : Invasive Cardiology (2017) - Edwards Lifesciences : invasive Cardiology (2017) - CSL Behring : Invasive Cardiology (2018) - Polares Medical : Invasive Cardiology (2018) <p>D - RESEARCH FUNDING UNDER YOUR DIRECT/PERSONAL RESPONSIBILITY (TO DEPARTMENT OR INSTITUTION) FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - St. Jude Medical : General Cardiology (2017) - Amgen Inc. : General Cardiology (2017)

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2018.

Expert	Type of Relationship with Industry
Windecker Stephan	<ul style="list-style-type: none"> - Symetis SA : Invasive Cardiology (2017) - Biotronik : Invasive Cardiology (2017) - Terumo Inc : Invasive Cardiology (2017) - Abbott : General Cardiology (2017-2018) - Boston Scientific : General Cardiology (2017-2018) - Edwards Lifesciences : General Cardiology (2018) - Medtronic : General Cardiology (2018) - Biotronik : General Cardiology (2018) - Amgen Inc : General Cardiology (2018) - Bristol Myers Squibb : General Cardiology (2018) - Bayer AG : General Cardiology (2018) - Sinomed : General Cardiology (2018) <p>2- Other Positions of Influence</p> <p>2.4 - Any other interest (financial or otherwise) that should be declared in view of holding an ESC position.</p> <ul style="list-style-type: none"> - Deputy Editor JACC CV Interventions Section Editor Uptodate Board Member SITEM (Swiss Institute of Translational and Entrepreneur Medicine) Advisor ECRI (European Cardiovascular Research Institute) Course Director, PCR (2017-2018)